Formulation and Evaluation of Pitavastatin Nanosuspension by Nannapaneni Nagajyothi,
FORMULATION AND EVALUATION OF PITAVASTATIN 
NANOSUSPENSION 
A Dissertation submitted to 
THE TAMILNADU Dr.M.G.R. MEDICAL UNIVERSITY 
Chennai-600032 
 
In partial fulfillment of the requirements for the award of degree of 
MASTER OF PHARMACY 
IN 
PHARMACEUTICS 
 
 
Submitted by 
 
REG. NO: 26115403 
 
Under the Guidance of 
 
M. DHANALAKSHMI, M.Pharm 
 
 
 
DEPARTMENT OF PHARMACEUTICS 
SWAMY VIVEKANANDHA COLLEGE OF PHARMACY 
ELAYAMPALAYAM 
TIRUCHENGODE-637205 
TAMIL NADU. 
 
SEPTEMBER-2013 
     
  
     CERTIFICATES 
 
 
 
 
 
 
 
 
 SWAMY VIVEKANANDHA COLLEGE OF PHARMACY 
 
Elayampalayam, Tiruchengode, 637 205 
Namakkal (DT), Tamilnadu. 
Phone: 04288-234417 (8lines) 
Fax: 04288-234417                                              
 
 
Dr. S. MOHAN KUMAR, M.Pharm., Ph.D., 
Principal  
 
 
 
 
 
CERTIFICATE 
  
  This is to certify that the dissertation entitled “FORMULATION AND 
EVALUATION OF PITAVASTATIN NANOSUSPENSION” submitted to The Tamilnadu 
Dr. M.G.R Medical University, Chennai, is a bonafide project work of Reg. No: 
26115403, in the Department of Pharmaceutics, Swamy Vivekanandha College of 
Pharmacy, Tiruchengode in partial fulfillment for the degree of Master of Pharmacy 
under the guidance of Miss. M.DHANALAKSHMI, M.Pharm., Swamy Vivekanandha 
College of Pharmacy Tiruchengode. 
 
 
 
                                                                       
 
 
                                                                        
 
[Dr. S. MOHAN, M.Pharm., Ph.D.,] 
 
 
 
 
 
 
   SWAMY VIVEKANANDHA COLLEGE OF PHARMACY 
 
Elayampalayam, Tiruchengode, 637 205 
                                      Namakkal (DT), Tamilnadu. 
                                      Phone: 04288-2344178lines)  
                                    Fax: 04288-234417                                       
 
 
Dr. N. N. RAJENDRAN, M.Pharm., Ph.D., 
Director of P.G Studies and Research 
 
 
 
 
CERTIFICATE 
 
 This is to certify that the dissertation entitled “FORMULATION AND 
EVALUATION OF PITAVASTATIN NANOSUSPENSION” submitted to The Tamilnadu 
Dr. M.G.R. Medical University, Chennai, is a bonafide project work of Reg. No: 
26115403, in the Department of Pharmaceutics, Swamy Vivekanandha College of 
Pharmacy, Tiruchengode in partial fulfillment for the degree of Master of Pharmacy 
under the guidance of Miss. M.DHANALAKSHMI, M.Pharm., Swamy Vivekanandha 
College of Pharmacy, Tiruchengode. 
 
 
 
 
 
 
 
                         [N. N. RAJENDRAN]         
 
 
 
 
 
                      
 
 
SWAMY VIVEKANANDHA COLLEGE OF PHARMACY 
                                      Elayampalaym, Tiruchengode, 637205 
                               Namakkal (DT), Tamilnadu. 
                              Phone: 04288-234417(8lines) 
                              Fax: 04288-234417                           
 
Prof. R. NATARAJAN, M .Pharm., (Ph.D), 
Head, Department of Pharmaceutics 
  
 
 
 
CERTIFICATE 
  
  This is to certify that the Dissertation entitled “FORMULATION AND 
EVALUATION OF PITAVASTATIN NANOSUSPENSION” submitted to The Tamilnadu 
Dr. M.G.R. Medical University, Chennai, is a bonafide project work of Reg. No: 
26115403, carried out in the Department of Pharmaceutics, Swamy Vivekanandha 
College of Pharmacy, Tiruchengode in partial fulfillment for the degree of Master of 
Pharmacy under the guidance of Miss. M.DHANALAKSHMI, M.Pharm., Swamy 
Vivekanandha College of Pharmacy, Tiruchengode. 
 
               
 
 
 
 
 
                                                                                                     [R. NATARAJAN] 
 
 
 
 
 
 
                                                                                                                 
SWAMY VIVEKANANDHA COLLEGE OF PHARMACY 
Elayampalaym, Tiruchengode, 637205 
Namakkal (DT), Tamilnadu. 
Phone: 04288-2344178lines)  
Fax: 04288-234417                               
 
   
 
 M. DHANALAKSHMI, M.Pharm., 
  Project guide 
 
 
CERTIFICATE 
 
              This is to certify that the Dissertation entitled “FORMULATION AND 
EVALUATION OF PITAVASTATIN NANOSUSPENSION” submitted to The 
Tamilnadu Dr. M.G.R. Medical University, Chennai, is a bonafide project work of 
Reg No: 26115403 in the Department of Pharmaceutics, Swamy Vivekanandha 
College of Pharmacy, Tiruchengode in partial fulfillment for the degree of Master of 
Pharmacy under my the guidance.  
                     This work is original and has not been submitted earlier for the 
award of any other degree or diploma of this or any other university.                                                                                              
 
 
 
 
 
 
   
                                                                                           [M. DHANALAKSHMI] 
         
 
  
 
 
Dedicated to 
My parent’s sister  
and fiends
 
 
 
 
 
  
 
 ACKNOWLEDGEMENT 
 
 
 
 
 
 
ACKNOWLEDGEMENT 
 
 The Joyness, satisfaction and euphoria that comes along with successful 
completion of any work would be incomplete unless we mention names of the people 
who made it possible, whose constant guidance and encouragement served as a beam of 
light crowned out effects. 
 First and foremost I bow down before Lord Almighty for his splendid 
blessings and care in completing my project work and throughout my life till this very 
second. 
 I render my sincere thanks to our honorable Chairman and Secretary, VIDHYA 
RATNA, Prof. DR. M. KARUNANITHI,  B.Pharm., M.S., Ph.D, D.Litt., for 
providing all facilities for my study and rendering his noble hand in the upliftment of 
women education in all the disciplines. 
 I consider it as a great honour to express my heartfelt appreciation to my guide 
Miss. M.Dhanalakshmi, M. Pharm., and Thank for her willingness to offer continuous 
guidance, support and encouragement, which are driving forces for me to complete this 
thesis. Her vast knowledge, her attitude to research and skill of presentation have been an 
invaluable resources to me. She is an admirable professor and will always be a role model 
for me. 
 It is difficult to overstate my gratitude to Dr. S. MOHAN, M.Pharm., PhD., 
and Principal of our institution. His enthusiasm and integral view on research and his 
mission for providing ‘only high-quality work and not less’, has made a deep impression 
on me. I owe him lots of gratitude for having me shown this way of research. 
I am elated to place on record my profound sense of gratitude to Dr. N. N. 
RAJENDRAN, M. Pharm., Ph.D., Director of PG studies and research. I am grateful to 
both for his caring supervision and enthusiastic involvement in this project and his 
supportive suggestions and comments. 
 It would be unwise if I forget to express my sincere thanks and gratitude to 
Prof. R.NATARAJAN, M.Pharm. (Ph.D),   Mr. K.MOHAN KUMAR. M.Pharm. 
and Mrs. R.SUBHASINI. M.Pharm, (Ph.D), Mrs. M. RANGA PRIYA, M.Pharm., 
(Ph.D), Department of Pharmaceutics for their immense support in all the aspects of my 
study. 
  I express my profound sense of gratitude to Mr. JAMBULINGAM. M.Pharm, 
Department of Pharmaceutical analysis for rendering his voluntary and friendly support 
during my project. 
 I take this opportunity to tell my special thanks to Miss. Latha & Mrs. 
P.Menaka, for their help and support in all my laboratory tests.  
 I owe my sincere thanks to my Parents, Sisters and Grandmother who cared 
for my well-being and had spent their times in shaping my character, conduct and my life. 
Without their moral support I am nothing and I dedicate all my achievements at their feet.  
 Friends are treasures to me and it is very difficult to overstate my thanks to all 
my friends and colleagues T.Sreelatha, V.V Deepthi, P.Swathi, A.Srujitha, 
B.Mahendra Babu, A.Sai kiran, B.Jagadeesh Kumar. It has been my happiest time to 
study, discuss, laugh and play with them all.  
 Also, I would like to thank The Tamil Nadu Dr. M.G.R. Medical University 
for providing a nice environment for learning. 
 I feel delighted to express my whole hearted gratitude to all those who gave 
their helping hands in completing my course and my project successfully.                                                                           
                                                                                                                                                          
 
                                                                                                                                  
 
                                                                                                      
 
                                                                                NANNAPANENI NAGAJYOTHI 
                                                                                     Reg.No:26115403   
 
 
 
 
 
LIST OF ABBREVIATIONS: 
 
 
Conc.    Concentration 
0C    Degree Centigrade 
Mm    Millimeter 
%      Percentage 
DSC    Differential scanning colorimetry 
nm    Nanometer 
gm    Gram 
mg     Milligram 
hr    Hours 
Ȝ max   Absorption maxima 
Min,    min Minute 
PVP   Polyvinylpyrrolidone 
ȝg,mcg   Micro gram 
rpm   Rotations per minute 
SLS   Sodium lauryl sulfate 
UV spectroscopy  Ultra-Violet spectroscopy 
R2    Regression Coefficient 
USP   United States Pharmacopoeia 
IP      Indian pharmacopoeia 
No.    Number 
 
  
 
    CONTENTS
                                                      
 
 
 
 
 
 
 CONTENTS 
S.NO TITLE PAGE NO 
1. INTRODUCTION 1 
2. REVIEW OF LITERATURE 3 
3. AIM AND OBJECTIVE 45 
4. PLAN OF WORK 47 
5. PROFILES 48 
  Drug profile  
  Polymer profile  
  Excipients profile  
6. MATERIALS 58 
7. METHODOLOGY 60 
  Construction of standard curve   
  Preformulation studies  
  Formulation of nanosuspension  
  Physic-chemical Characterisation of 
nanosuspension 
 
  In vitro drug release studies  
8. RESULTS 67-104 
9. DISCUSSION 105-106 
10. CONCLUSION 107 
11. REFERENCE 108 
 
 
 
 LIST OF TABLES 
TABLE 
NO PARTICULARS 
PAGE 
NO. 
1. 
 Initial classification based on total cholesterol, HDL, 
LDL and Triglyceride 
4 
2. Medication Routes and Administration 8-10 
3. Comparative size illustration 12 
4. 
Advantages of Nanosuspensions over conventional 
formulations 
18 
5. Various examples of solvents used in nanosuspensions 
formulation 
21 
6. Advantages and disadvantages of various preparation 
techniques of nanosuspensions 
32 
7. Some characteristics of (α, ȕ, Ȗ, δ). 57 
8. Ingredients used for the experiment 58 
9. Instruments used for the experiment 59 
10. Formulation of pitavastatin nanosuspensions 63 
11. Data for standard calibration curve of Pitavastatin drug 
in0.1n HCl buffer 
68 
12. 
Results of solubility and drug entrapment efficiency 
70 
13. Pitavastatin nanosuspension of ȕ-cyclodextrin & Tween 
80 
75 
14. 
Pure pitavastatin 
76 
15. ȕ-cyclodextrin 77 
16. 
Tween 80 
78 
17-32. Dissolution profile of formulation (F0-F15) in ph 1.2 
buffer 
85-100 
33. 
Comparative cumulative % drug release of 
formulations f0-f15 
 
101-103 
 
 
 LIST OF GRAPHS 
GRAPH 
NO PARTICULARS 
PAGE 
NO. 
1. Ȝmax curve of pitavastatin 67 
2. Standard curve of pitavastatin 68 
3-18. In-vitro release  of formulations f0 – f15 85-100 
19. Comparative study of nanosuspension formulations 104 
 
 
 
 
 
 
  
 
 
  INTRODUCTION
1 
 
1.INTRODUCTION 
 
Oral route has been commonly adopted and most convenient route for the drug 
delivery. Oral drug delivery system has received more attention in the pharmaceutical 
field, because of its more flexibility in designing the dosage form than the other drug 
delivery systems [1]. In recent years novel drug delivery systems like nanosuspensions 
draws a considerable attention in search for improving bioavailability of poorly soluble 
drugs [2]. 
 
It is estimated that more than 1/3 of the compounds being developed by the 
pharmaceutical industry are poorly water soluble. The solubility/dissolution behavior of a 
drug is key factor to its oral bioavailability. An improvement of oral bioavailability of 
poor water-soluble drugs remains one of the most challenging tasks of drug development. 
To overcome poor solubility, many approaches have been studied. They are generally salt 
formation, use of surfactant, use of prodrugs and micronization. In micronization, the 
particle size of a drug powder is reduced to a micron scale size (typically 2-10 micron), 
which increases the specific surface area and dissolution rates. However, many new drugs 
are so poorly soluble that micronization is not sufficient, which motivated the 
development of nanoscale systems. By decreasing the particle size from a micron to a 
nanometer scale, there is a significant increase in the surface area and related dissolution 
rate [3, 4].  
 
Nanosuspensions are sub-micron colloidal dispersions of pure drug particles in an 
outer liquid phase. Nanoparticle engineering enables poorly soluble drugs to be 
formulated as nanosuspensions alone, or with a combination of pharmaceutical 
excipients. Nanosuspensions engineering processes currently used are precipitation [5], 
high pressure homogenization [6], and pearl milling [7], either in water or in mixtures of 
water and water miscible liquids or non-aqueous media [8]. 
 
Nanoprecipitation method presents numerous advantages, in that it is a 
straightforward technique, rapid and easy to perform. In this method, the drug is dissolved 
in an organic solvent such as acetone, acetonitrile, methanol or ethyl acetate. The organic 
solvent is evaporated either by reducing the pressure or by continuous stirring. Particle 
size was found to be influenced by the type of stabilizer, concentrations of stabilizer, and 
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homogenizer speed. In order to produce small particle size, often a high-speed 
homogenization or ultrasonication may be employed. The super saturation is further 
accentuated by evaporation of drug solvent. This yields to the precipitation of the drug. 
High shear force prevents nucleus growth and Oswald’s ripening [9]. 
 
Pitavastatin is a lipid lowering agent. Synthesis of cholesterol via competitive 
inhibition of the liver enzyme, this is a principal metabolite and an inhibitor of 3-
hydroxy- 3-methylglutaryl-coenzyme-A (HMG Co-A) reductase, the enzyme that 
catalyses an early and Rate-limiting step in the biosynthesis of cholesterol [10]. Pitavastatin   
is a white to pale-yellow powder, crystalline, nonhygroscopic powder, insoluble in water 
and 0.1N HCl (30mg/ml and 60mg/ml, respectively).  Pitavastatin belongs to BCS class-
II drug category in which the drug is poorly soluble and highly permeable. It is generally 
considered that compounds with very low aqueous solubility will show dissolution rate-
limited absorption. Improvement of aqueous solubility in such case is a valuable goal to 
improve therapeutic efficacy. The dissolution rate is a function of the solubility and the 
surface area of the drug, thus, dissolution rate will increase if the solubility of the drug is 
increased, and it will also increase with an increase in the surface area of the drug [11, 12]. 
 
In this present study, an extensive literature survey indicates no reports available 
on the pharmaceutical approaches for improving the solubility of Pitavastatin. Therefore 
the present study aimed to develop nanosuspension of Pitavastatin by nanoprecipitation 
technique and evaluate for physicochemical and in-vitro release characterization. 
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2. REVIEW OF LITERATURE 
2.1. CHOLESTEROL 
Cholesterol is a waxy substance made by animal liver and also supplied in diet 
through animal products such as meats, poultry, fish and dairy products. Cholesterol is 
needed in the body to insulate nerves, make cell membranes and produce certain 
hormones, and it is an important lipid in some membranes. However, the body makes 
enough cholesterol, so any dietary cholesterol isn't needed. Cholesterol can be both good 
and bad. High-density lipoprotein (HDL) is good cholesterol and low-density lipoprotein 
(LDL) is bad cholesterol. High cholesterol in serum is a leading risk factor for human 
cardiovascular disease such as coronary heart disease and stroke. 
 
Chemical Structure of Cholesterol: 
 
 
Good Cholesterol and Bad Cholesterol: 
HDL is called “good cholesterol” that is good for the cardiovascular system and LDL 
is called “bad cholesterol” that is bad for the cardiovascular system. These are the form in 
which cholesterol travels in the blood. LDLs have little protein and high levels of 
cholesterol and HDL has a lot of protein and very little cholesterol. LDL is the main 
source of artery clogging plaque. HDL actually works to clear cholesterol from the blood. 
The standard test of cholesterol is done after a 9-12 hours fast without food, liquids or 
pills. It gives information about total cholesterol, LDL, HDL and triglycerides (blood 
fats). The cholesterol content in blood is the key data for the health information of 
cholesterol related (Table 1). 
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Table 1. Initial classification based on total cholesterol, HDL, LDL and 
Triglyceride 
CHOLESTEROL CHOLESTEROL LEVEL CATEGORY 
Total Cholesterol 
 
Less than 200 mg/dl Desirable level. 
200 to 239 mg/dl 
Borderline high for heart 
disease. 
240 mg/dl and above 
High blood cholesterol. 
A person with this level 
has more than twice the 
risk of heart disease as 
someone whose 
cholesterol is below 200 
mg/dl. 
HDL Cholesterol 
Less than 40 mg/dl 
Low HDL cholesterol. A 
major risk factor for 
heart disease. 
40 to 59 mg/dl 
The higher HDL level, 
the better. 
60 mg/dl and above 
High HDL cholesterol. 
An HDL of 60 mg/dl and 
above is considered 
protective against heart 
disease. 
LDL Cholesterol 
Less than 100 mg/dl Optimal 
100 to 129 mg/dl Near or above optimal 
130 to 159 mg/dl Borderline high 
160 to 189 mg/dl High 
190 mg/dl and above Very high 
Triglyceride 
Less than 150 mg/dl Normal 
150-199 mg/dl Borderline high 
200-499 mg/dl High 
 
Triglyceride: 
Triglycerides are another fat in the bloodstream. High levels of triglycerides are also 
linked to heart disease. Triglyceride is the most common type of fat in the body. Many 
people who have heart disease or diabetes have high triglyceride levels. Normal 
triglyceride levels vary by age and sex. A high triglyceride level combined with low HDL 
cholesterol or high LDL cholesterol seems to speed up atherosclerosis, which is the 
buildup of fatty deposits in artery walls that increase the risk for heart attack and stroke. 
People should reduce the amount of saturated fat, trans-fat, cholesterol and total fat in 
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their diet. Some studies have shown a higher mortality in people with low cholesterol 
levels - that is, lower than 160 mg/dl. These deaths are from non-coronary causes (some 
cancers, chronic respiratory disease, liver disease and trauma). On the other hand, some 
evidence suggests that total cholesterol levels below 160 mg/dl are not dangerous. In 
many countries a major portion of the population has cholesterol levels in this range 
throughout life without serious health problems. Also, less than 6 percent of the American 
population has a cholesterol level below 160 mg/dl. It's rarely necessary to lower total 
cholesterol below that. 
 
Hyperlipidemic Drugs: 
 
Hyperlipidemia is an elevation of lipids (fats) in the bloodstream. These lipids include 
cholesterol, cholesterol esters (compounds), phospholipids and triglycerides. They're 
transported in the blood as part of large molecules called lipoproteins. These are the five 
major families of blood (plasma) lipoproteins: (1) chylomicrons, (2) very low-density 
lipoproteins (VLDL), (3) intermediate-density lipoproteins (IDL), (4) low-density 
lipoproteins (LDL), (5) high-density lipoproteins (HDL). When hyperlipidemia is defined 
in terms of class or classes of elevated plasma lipoproteins, the term hyperlipoproteinemia 
is used. Hypercholesterolemia is the term for high cholesterol levels in the blood. 
Hypertriglyceridemia refers to high triglyceride levels in the blood.  
 
Medications: 
The main goal in lowering cholesterol is to lower your LDL and raise your HDL. 
To lower cholesterol, eat a heart-healthy diet, exercise regularly, and maintain a healthy 
weight. Some may also need to take cholesterol lowering medications. Cholesterol-
lowering medicine is most effective when combined with a low-cholesterol diet and 
exercise program. The drugs of first choice for elevated LDL cholesterol are the HMG 
CoA reductase inhibitors, e.g. lovastatin, Pravastatin and simvastatin. Statin drugs are 
very effective for lowering LDL cholesterol levels and have few immediate short-term 
side effects [13]. They are easy to administer, have high patient acceptance and have few 
drug-drug interactions. 
 
Type of hyperlipidemia: 
1. Primary hyperlipidemia  
2. Secondary hyperlipidemia  
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Anti-Hyperlipidemic drugs are mainly classified into 5 types
 [14]
:  HMG-CoA Reductase Inhibitors (HMGs or statins): Pravastatin, Simvastatin, 
pitavastatin, Atorvastatin, Fluvastatin, Lovastatin. (They are most potent LDL 
reducers)  Fibrates: E.g. Fenofibrate, Gemfibrozil, Clofibrate  Anion –exchange resins( bile acid sequestrates): E.g. Colesevelam, Colestipol, 
Cholestyramine  Nicotinic acid: E.g. NIACIN.   Cholesterol absorption inhibitors: E.g. Ezetimibe.   Other drugs E.g. Alpha-tocopherol acetate (vitamin E), Omega-3 marine 
triglycerides (Maxepa), Orlistat. 
Mechanism of action of statins:  Block the rate-limiting enzyme for endogenous cholesterol synthesis, hydroxy-
methylglutaryl Coenzyme A (HMG CoA) reductase.   Increased synthesis of LDL-receptors (up regulation) in the liver   Increased clearance of LDL from the circulation  
Note: Plasma total cholesterol and LDL-cholesterol fall to attain a maximum effect 1 
month after therapy. 
Therapeutic uses: 
These drugs are effective in lowering plasma cholesterol levels in all types of 
hyperlipidemia However, patients who are homozygous for familial hypercholesterolemia 
lack LDL receptors and therefore, benefit much less from treatment with these drugs. 
These drugs are often given in combination with other antihyperlipidemic drugs. 
Pharmacokinetics of statins: 
Pravastatin and Fluvastatin, Pitavastatin are almost completely absorbed after oral 
administration.   Oral doses of lovastatin and simvastatin are from 30 to 50 percent absorbed.  
 Pravastatin and Fluvastatin are active, whereas lovastatin and simvastatin must be 
hydrolyzed to their acid forms.  
 Excretion takes place through the bile and feces  
 Some urinary elimination also occurs.  
 Their half-lives range from 1.5 to 2 hours.  
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Note: 
1. Transient and minor abnormality of liver function tests. 
2. Myopathy and rhabdomyolysis (disintegration or dissolution of muscle and elevation of 
muscle enzymes (creatine, phosphokinase, CPK) the risk is greater in:  
 In patients with renal insufficiency  
 In patients taking drugs such as cyclosporine, itraconazole, erythromycin, 
Gemfibrozil, or niacin. Plasma creatine kinase levels should be determined 
regularly. 
 
ROUTE OF ORAL DRUG DELIVERY 
Definition:- 
A route of administration in pharmacy is the path by which a drug is taken into the 
body [15]. 
Oral route: - 
In this route the drug is placed in the mouth and swallowed. It is also called per 
oral (p.o.) 
Advantages of Oral route: 
• Convenient - Can be self administered, pain free & easy to take 
• Absorption - Takes place along the whole length of the gastro intestinal tract 
• Cheap - Compared to most other parenteral routes. 
Disadvantages of oral route: 
• Sometimes inefficient - only part of the drug may be absorbed. 
• First-pass effect - drugs absorbed orally are initially transported to the liver via 
the portal vein. 
• Irritation to gastric mucosa – nausea and vomiting. 
• Destruction of drugs by gastric acid and digestive juices. 
• Effect too slow for emergencies. 
• Unpleasant taste of some drugs. 
• Unable to use in unconscious patient. 
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Table 2: Medication Routes and Administration: 
[16]. 
Forms Acts In: Advantages Disadvantages Technique 
Tablet(pressed powder) 
30-60 
minutes 
 Easy to administer  Inexpensive  Can be removed 
(lavage 
 Not good in 
      emergencies  Can irritate GI tract  Absorption is 
unpredictable 
 Follow correct technique for 
”pouring” 
meds  Do not touch meds  Person should be up- not 
laying down  Offer fluids to help swallowing  Make sure the person swallows 
the meds 
Do not force person to take meds 
If person refuses medication try again 
a short time later; keep meds secure 
and labeled until administered 
Capsule (drug in a 
gelatin shell) 
30-60 
minutes 
  Same as above 
Time released 
(medication in gelatin 
cap; also called Long 
Acting, Sustained 
30-60 
minutes 
Drug is made to dissolve over 
a period of time and the 
effects last longer 
Can’t crush or chew Same as above 
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Release and/ or 
Spansule) 
Sprinkle (drug in a 
gelatin cap that can be 
opened to pour on 
food for 
administration) 
30-60 
minutes 
Can open cap and pour on 
food to administer 
Can’t chew sprinkles Same as above 
Enteric coated (drug 
coated with hard shell 
so it will pass the 
stomach and dissolve 
in the intestines) 
30-60 
minutes 
Will not cause stomach upset 
 
 
 
 
 
Can’t crush or chew Same as above 
Liquid Suspension 
(particles of drug 
suspended in a liquid 
agent) 
30-60 
minutes 
 Make sure you know if the 
person has an order to have 
liquids thickened to a specific 
consistency 
 
 
 
 
 Wash hands  Make sure you know how 
many “ml” or “cc” you need to 
pour to get the dose you have 
to give  Gently shake the bottle  Have medication label facing 
into palm of hand 
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 Use disposable medication cup 
for measuring liquid 
medications 
 
Liquid Suspension 
(continued) 
30-60 
minutes 
   Place cup on a flat surface at 
eye level  Pour the prescribed medication 
Syrups (med is 
dissolved in liquid 
with sugar and 
flavoring 
30-60 
minutes 
Same as Liquid Suspension Same as Liquid Suspension Same as Liquid Suspension 
Elixir (Med is 
dissolved in liquid 
with sugar, flavoring 
and alcohol) 
30-60 
minutes 
Same as Liquid Suspension Same as Liquid Suspension Same as Liquid Suspension 
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2.2. NANOTECHNOLOGY 
 
Nanotechnology, the term derived from the Greek word Nano, meaning dwarf, applies 
the principles of engineering, electronics, physical and material science, and 
manufacturing at a molecular or submicron level. The materials at nanoscale could be a 
device or a system or these could be supra molecular structures, complexes or 
composites. An early promoter of nanotechnology, Albert Franks, defined it as ‘that area 
of science and technology where dimensions and tolerances are in the range of 0.1nm to 
100nm’. Nano technology is expected to make significant advances in the mainstream 
biomedical applications, including in the areas of gene therapy, drug delivery, imaging, 
and novel drug discovery techniques [17]. 
 
Nanotechnology is hailed as a new generation of technology with the potential to 
revolutionise many facets of the world we live in. This includes virtually all aspects of 
daily life, including health and health care, the manufacturing and use of materials and 
equipment, the environment and protection thereof. It is said to be able to massively 
increase manufacturing production at significantly reduced costs. Products of 
nanotechnology will be smaller, cheaper, lighter yet more functional and require less 
energy and fewer raw materials to manufacture. However, the ‘revolution’ will not 
happen overnight and very large investments in research and development will be 
required in the process. 
 
Nanotechnology can be defined as having the following features  It involves research and technology development at the 1 nm –100 nm range.  It creates and uses structures that have novel properties because of their small size.  It builds on the ability to control or manipulate at the atomic and molecular scale. 
 
At the nano-scale the interactions and physics between atoms display ‘exotic’ 
properties that are absent at larger scale because at this level atoms leave the realm of 
classical physical properties behind and enter the realm of quantum mechanics. 
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                                     Table: 3 Comparative size illustrations 
100 m=1 m=1000 mm Human length (~1.7 m) 
10-1 m=10 cm 
 
 
10-2 m=1 cm 
 
 
10-3 m=1 mm=1000 µm 
Sand filter grain (0.5 mm=500 
µm) 
10-4 m=0.0001 m=100 µm 
Hair diameter (75 µm=75000 
nm) 
10-5 m=10 µm Red blood cells (5000 nm=5 µm) 
E.coli (2000 nm= 2 µm)  
10-6 m=1 µm=1000 nm 10-6 m=1 µm=1000 nm 
10-7 m=100 nm 
Virus (50 nm) Pore size of UF 
membrane (50-200 nm) Colloidal 
particles (20-100 nm) 
10-8 m=10 nm 
DNA molecule (2 nm wide 
Typical protein (3 nm diameter) 
10-9 m=1 nm Buck ball(1 nm) 
 
Nanotechnology includes a bewildering array of activities including: molecular 
manufacturing, supramolecular and self assembly/organization; biomimicry; Nanoparticle 
(e.g. Bucky balls and carbon Nano tubes), nanospheres, Nano cups and nanorods; 
nanobots (nanorobots); colloids, micelles, vesicles and Nano-emulsions; clathrate 
complexes and intercalation compounds. 
The National Science Foundation in the USA predicts that the global marketplace 
for goods and services using nanotechnologies will grow to $1 trillion by 2015, and there 
are already over 500 products being sold that claim they are made with nanoscale or 
engineered nanomaterials. These include products like self-cleaning windows, automobile 
paint, sunscreens, and tennis rackets. In the future, a marriage of nano- and biotechnology 
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will likely create a whole new generation of drugs, biomedical devices, and other 
solutions to some of our most challenging medical problems [18]. 
Nanotechnology in drug delivery 
The development of delivery systems for small molecules, proteins and DNA has 
been impacted to an enormous degree over the past decade by nanotechnology, and has 
led to the development of entirely new and somewhat unpredicted fields. For the 
pharmaceutical industry, novel drug delivery technologies represent a strategic tool for 
expanding drug markets. The technology can address issues associated with current 
pharmaceuticals such as extending product life (line extension), or can add to their 
performance and acceptability, either by increasing efficacy or improving safety and 
patient compliance [19]. This technology is permitting the delivery of drugs that are highly 
water- insoluble or unstable in the biological environment. Advantages of nano sizing of 
drugs has the potential to: Increase surface area, enhance solubility, increase rate of 
dissolution, increase oral bioavailability, more rapid onset of therapeutic action, decrease 
the dose needed, decrease fed/fasted variability and decrease patient to patient variability.  
        In recent trend, nano drug delivery may occur through gold nanospheres and rods, 
nanowires, nanotriangles, nanostars, nanocubes, and nanorice. The size of these nano 
configurations varies from 1 to 100 nm. Nanoplatforms include organic nanostructures, 
polymeric nanoparticle, lipid systems-liposomes, self assemblies-micelles, dendrimers, and 
carbon nanostructure-nanotubes. Inorganic nanostructures include metal nanoparticle and 
nanoshells, silicon nanostructure, nanocrystals, and quantum dots. Hybrid nanostructures, 
combining two to three of those previous listed can also be produced. Studies were 
described in which polymeric nanoparticles were used for tumor-targeted deliver. Gelatin-
based engineered nanoparticles have been used for gene delivery and multifunctional 
nanoemulsions for oral and intravenous delivery. Gadolinium-loaded nanoemulsion has 
been used in animals for brain imaging, and this technology could easily be used for 
imaging within the eye to observe the results of various drug delivery modalities. 
 
 
 
14 
 
The benefits of nanotechnology are 
 The lifespan of the blockbuster drugs can be resurrected by reformulating the 
drugs through novel drug delivery system.  The effective patent protection can be enhanced.  Drug delivery formulation involves low cost research compared to that for the 
discovery of new molecules.  Minimizing use of expensive drugs would reduce the cost of the product. 
 
Significance of drug delivery and targeting: 
Although opportunities to develop nanotechnology based efficient drug delivery 
systems extend into all therapeutic classes of pharmaceuticals, the development of 
effective treatment modalities for the respiratory, central nervous system and cardio 
vascular disorders remains a financially and therapeutically significant need. Many 
therapeutic agents have not been successful because of their limited ability to reach to the 
target tissue. In addition, the faster growth opportunities are expected in developing 
delivery systems for anti cancer agents, hormones and vaccines because of safety and 
efficacy shortcomings in their conventional administration modalities. For example, in 
cancer chemotherapy, cytostatic drugs damage both malignant and normal cells alike. 
Thus, a drug delivery strategy that selectively targets the malignant tumor is very much 
needed. Additional problems include drug instability in the biological milieu and 
premature drug loss through rapid clearness and metabolism. Similarly, high protein 
binding of certain drugs such as protease inhibitors limits their diffusion to the brain and 
other organs. However, nanotechnology for drug delivery applications may not be 
suitable all drugs, especially those drugs that are less potent because the higher dose of 
the drug would make the drug delivery system much larger, which would be difficult to 
administer.   
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2.3. NANOSUSPENSION 
 
A pharmaceutical nanosuspension is defined as “very finely disperaqueous 
vehicle, stabilized by surfactants, for either oral and topical use or parenteral and 
pulmonary administration, with reduced particle size, leading to an increased dissolution 
rate and therefore improved bioavailability”. The diameter of the suspended particle is 
less than 1 ȝ min size (i.e. 0.1nm-1000 nm) [20, 21]. The particle size distribution of the 
solid particles in nanosuspensions is usually less than one micron with an average particle 
size ranging between 200 and 600 nm.3 An increase in the dissolution rate of micronized 
particles (particle size < 10 ȝm) is related to an increase in the surface area and 
consequently the dissolution velocity. Nano size particles can increase dissolution 
velocity and saturation solubility because of the vapor pressure effect [22]. 
Need of Nanosuspensions
 
More than 40% of drugs are poorly soluble in water, so they show problems in 
formulating them in conventional dosage forms. Also, for class II drugs which are poorly 
soluble in aqueous and organic media, the problem is more complex [23]. Preparing 
nanosuspensions is preferred for such compounds that are insoluble in water (but are 
soluble in oil) with high log P value. Various approaches to resolve problems of low 
solubility and low bioavailability micronization, co-solvency, oily solution, salt 
formation- some other techniques are liposomes, emulsions, microemulsion, solid 
dispersion, ß- cyclodextrin inclusion complex etc. But, many of these techniques are not 
universally applicable to all drugs [23]. In these cases nanosuspensions are preferred. In 
case of drugs that are insoluble in both water and in inorganic media instead of using 
lipidic systems, nanosuspensions are used as a formulation approach. It is most suitable 
for the compounds with high log P value, high melting point, and high dose. 
Nanosuspensions can be used to enhance the solubility of drugs that are poorly soluble in 
aqueous as well as lipid media. As a result, the rate of flooding of the active compound 
increases and the maximum plasma level is reached faster (e.g., oral or intravenous (IV) 
administration of the Nanosuspensions).  
This is one of the unique advantages that it has over other approaches for enhancing 
solubility. It is useful for molecules with poor solubility, poor permeability or both, which 
16 
 
poses a significant challenge for the formulators. Major issues associated with poorly 
water-soluble compounds [24]: 
 Poor bioavailability.  Inability to optimize lead compound selection based on efficacy and safety.   Fed/fasted variation in bioavailability.   Lack of dose-response proportionality.   Suboptimal dosing.   Use of harsh excipients, i.e., excessive use of co-solvents and other excipients.   Use of extreme basic or acidic conditions to enhance solubilization. 
 
Although, all marketed products, currently are produced by so-called ‘top-down 
techniques’, in which the Nanoparticle are obtained through size reduction into the 
submicron-range, bottom-up techniques and especially controlled precipitation method, 
are methods of interest for nanozation of poorly soluble drugs. In this method, without 
any harsh conditions and only with simple equipments one could reduce the particle size 
to few hundred nanometers range. Therefore, whatever method which is used for the 
production of Nanosuspensions, a careful evaluation of the type and concentration of the 
stabilizer is a critical stage for the successful production of nanosuspensions. Both 
polymeric and surfactant stabilizers can be used for this purpose [25]. 
Nanosuspensions differ from Nanoparticle, which are polymeric colloidal carriers of 
drugs (Nanospheres and nanocapsules), and from solid-lipid Nanoparticle (SLN), which 
are lipidic carriers of drug. The key difference from conventional formulations of 
suspensions is that the particle size distribution of the solid particles in Nanosuspensions 
is usually less than 1 ȝm (i.e. 0.1nm-1000nm), with an average particle size range 
between 200–600 nm. On the other hand, the particle diameter required in most good 
pharmaceutical suspensions, is 1 to 50 ȝm. In Nanosuspensions, the overall 
bioavailability is improved by an increase in surface area and saturation solubility via 
particle size reduction. This system cannot be achieved by the conventional milling 
techniques. (Figure 1). [20] 
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Major Advantages of Nanosuspensions
 [23] 
(Table 4) 
 Its general applicability to most drugs and its simplicity.   Can be applied for the poorly water soluble drugs.   Can be given by any route.   Reduced tissue irritation in case of subcutaneous/intramuscular administration.   Rapid dissolution and tissue targeting can be achieved by IV route of 
administration.   Oral administration of Nanosuspensions provide rapid onset, reduced fed/fasted 
ratio and improved bioavailability.   The absorption from absorption window of the drugs can be increased, due to 
reduction in the particle size (Figure 2).   Higher bioavailability and more consistent dosing in case of ocular administration 
and inhalation delivery (Figure 3 & 4).   Drugs with high log P value can be formulated as Nanosuspensions to increase the 
bioavailability of such drugs.   Improvement in biological performance due to high dissolution rate and saturation 
solubility of the drug.   Ease of manufacture and little batch-to-batch variation.   Long term physical stability (Due to absence of Ostwald ripening).   Nanosuspensions can be incorporated in tablets, pellets, hydrogel and 
suppositories are suitable for various routes of administration.   Increasing the amorphous fraction in the particles, leading to a potential change in 
the crystalline structure and higher solubility.   Possibility of surface-modification of Nanosuspensions for site specific delivery.   Possibility of large-scale production, the pre-requisite for the introduction of a 
delivery system to the market.  
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Table 4: Advantages of Nanosuspensions over conventional formulations
 [20]
: 
 
Figure 1
[24]
: the plot demonstrates the increase in surface area obtained when solids 
are fractured from the micron-size range (microparticles) to the nanometer-size particles 
used in the various Nanoparticle formulations to improve the performance of poorly 
water-soluble compounds. 
Route of Administration 
 
Disadvantages of 
Conventional 
Formulations 
Benefits of 
Nanosuspensions 
Oral 
 
Slow onset of action/ poor 
absorption  
Rapid onset of action/ 
improved solubility so 
improved bioavailability  
Reduced fed/fasted ratio  
Ocular 
 
Lachrymal wash off/ low 
bioavailability  
Higher bioavailability/ dose 
consistency Lesser irritation  
Intravenous 
 
Poor dissolution/ non-
specific action  
Rapid dissolution/ tissue 
targeting Prolonged 
retention time in systemic 
circulation  
Intramuscular Low patient compliance 
due to pain  
Reduced tissue irritation  
High bioavailability Rapid 
onset of action  
Inhalation Low bioavailability due to 
low solubility  
Rapid dissolution/ high 
bioavailability/ dose 
regulation  
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Figure 2
[24]
: The diagram demonstrates one of the primary issues associated with 
poorly water-soluble molecules whose bioavailability is dissolution-rate limited. On the 
left, large drug particles cannot adequately dissolve, which results in the inability to be 
absorbed. On the right, nanometer drug particles are rapidly dissolved during transit 
through the gut, thus maximizing absorption and improving bioavailability. 
 
 
Figure 3
[24]
: A dose-escalation study is shown demonstrating dose proportionality for 
a Nanoparticle formulation of a poorly water-soluble compound. 
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Figure 4
[24]
: The bioavailability of a poorly water-soluble model compound 
formulated as a Nanoparticle dispersion (red) or as a conventional crude suspension 
(yellow).  
Formulation Considerations: 
Stabilizer
 [23]
: 
Stabilizer plays an important role in the formulation of nanosuspensions. In the 
absence of an appropriate stabilizer, the high surface energy of nanosized particles can 
induce agglomeration or aggregation of the drug crystals. The main function of a 
stabilizer is to wet the drug particles thoroughly, and to prevent Ostwald’s ripening and 
agglomeration of nanosuspensions in order to yield a physically stable formulation by 
providing steric or ionic barriers. The type and amount of stabilizer has a pronounced 
effect on the physical stability and in-vivo behavior of nanosuspensions. In some cases, a 
mixture of stabilizers is required to obtain a stable nanosuspension. The drug-to-stabilizer 
ratio in the formulation may vary from 1:20 to 20:1 and should be investigated for a 
specific case e.g. Cellulosics, Poloxamer, Polysorbates, Lecithin and Povidone. Lecithin 
is the stabilizer of choice if one intends to develop a parenterally acceptable and 
autoclavable nanosuspensions. 
Organic solvents
 [23]
: 
Organic solvents may be required in the formulation of nanosuspensions if they are to 
be prepared using an emulsion or microemulsion as a template. As these techniques are 
still in their infancy, elaborate information on formulation considerations is not available. 
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The acceptability of the organic solvents in the pharmaceutical arena, their toxicity 
potential and the ease of their removal from the formulation need to be considered when 
formulating nanosuspensions using emulsions or microemulsion as templates (Table 5). 
Partially water-miscible organic solvents like glycols can be used as the internal phase of 
the microemulsion when the nanosuspensions are to be produced using a microemulsion 
as a template. 
Surfactants
 [26]
: 
Surfactants are incorporated to improve the dispersion by reducing the interfacial 
tension. They also act as wetting or deflocculating agents e.g. Tween 80 and Span - 
widely used surfactants. 
Co-surfactants
:
 
The choice of co-surfactant is critical when using microemulsion to formulate 
nanosuspensions. Since co-surfactants can greatly influence phase behavior, the effect of 
co-surfactant on uptake of the internal phase for selected microemulsion composition and 
on drug loading should be investigated e.g. Transcutol, glycofurol, ethanol and Iso-
propanol - safely used as co-surfactants. Also, bile salts and dipotassiumglycerrhizinate 
can be used as co-surfactants. 
Other additives
 [23]
: 
Nanosuspensions may contain additives such as buffers, salts, polyols, osmogent and 
cryoprotectant, depending on either the route of administration or the properties of the 
drug moiety. 
Table 5: Various examples of solvents used in nanosuspensions formulation 
Type of solvent Name Remarks 
 
Water-miscible solvents 
 
Ethanol, Iso-propanol etc. 
Pharmaceutically acceptable 
&less hazardous. 
Partially water-miscible 
solvents 
Ethyl acetate, ethyl formate, 
butyl lactate, triacetin, 
propylene carbonate, benzyl 
alcohol etc. 
Preferred in the formulation 
over the conventional 
hazardous solvents, such as 
dichloromethane. 
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Properties of nanosuspensions: 
Physical long-term stability
 [23]
: 
Another special feature of nanosuspensions is the absence of Ostwald ripening, 
which is suggestive of their long-term physical stability. Ostwald ripening is responsible 
for crystal growth and subsequently formation of microparticles. Ostwald ripening is 
caused by the differences in dissolution pressure/saturation solubility between small and 
large particles. Molecules diffuse from the higher concentrated area around small 
particles (higher saturation solubility) to areas around larger particles possessing a lower 
drug concentration. This leads to the formation of a supersaturated solution around the 
large particles and consequently to drug crystallization and growth of the large particles. 
The diffusion process of the drug from the small particles to the large particles leaves an 
area around the small particles that is not saturated any more, consequently leading to 
dissolution of the drug from the small particles and finally completes disappearance of the 
small particles. 
Internal structure of Nanosuspensions
 [20]
: 
The high-energy input during disintegration process causes structural changes inside 
the drug particles. When the drug particles are exposed to high-pressure homogenization, 
particles are transformed from crystalline state to amorphous state. The change in state 
depends upon the hardness of drug, number of homogenization cycles chemical nature of 
drug and power density applied by homogenizer. 
Adhesiveness
 [20]
: 
There is a distinct increase in adhesiveness of ultra-fine powders compared to coarse 
powders. This adhesiveness of small drug nanoparticle can be exploited for improved oral 
delivery of poorly soluble drugs. A drastically remarkable report is that of the increase in 
bioavailability for danazol from 5 % (as macrosuspension) to 82% (as nanosuspensions). 
Crystalline state and morphology
 [20]
: 
A potential change in the crystalline structure of nanosuspensions saying increasing 
the amorphous fraction in the particle or even creating completely amorphous particles is 
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a characteristic of consideration. The application of high pressures during the production 
of nanosuspensions was found to promote the amorphous state. 
Increase in Saturation Solubility and Dissolution Velocity of drug
 [21]
: 
Dissolution of drug is increased due to increase in the surface area of the drug 
particles from micrometers to the nanometer size. According to Noyes-Whitney equation 
(Equation no.1), dissolution velocity increases due to increase in the surface area from 
micron size to particles of nanometer size. 
dx/dt = [(D x A)/ h] [Cs-X/V] -----Equation (1) 
 
Preparation Methods of nano- suspension: 
There are different methods of Nanosuspensions preparation (Figure 6) [20] 
 Homogenization in water (Disso Cubes).  Media milling (Nanocrystals or Nanosystems).  Homogenization in non-aqueous media (Nanopure).  Combined precipitation and homogenization (Nanoedge).  Nanojet technology.  Emulsification-solvent evaporation technique.  Hydrosol method.  Supercritical fluid method.  Dry co-grinding.  Emulsion as template.  Microemulsion as template. 
Current techniques used to obtain drug nanoparticle can be divided into two 
categories: 
Bottom up techniques: 
It is the technique in which the nano size is obtained by increasing the size of 
particles from molecular range to nanorange [22]. The conventional methods of 
precipitation (‘Hydrosol’) are called Bottom up technology. Using a precipitation 
24 
 
technique, the drug is dissolved in an organic solvent and this solution is mixed with a 
miscible anti-solvent. In the water-solvent mixture, the solubility is low and the drug 
precipitates. Basic challenge is that during the precipitation procedure growing of the 
crystals need to be controlled by addition of surfactant to avoid formation of 
microparticles. 
Advantage: 
 The use of simple and low cost equipments. 
Limitations: 
 The drug needs to be soluble in at least one solvent and the solvent needs to be 
miscible with non-solvent.  Moreover, it is not applicable to the drugs, which are poorly soluble in both 
aqueous and non-aqueous media. 
Top down techniques: 
The techniques in which Nano size range of particles is obtained by reduction in 
size of larger particles [22]. 
High Pressure Homogenization (Disso Cubes): 
Homogenization involves the forcing of the suspension under pressure through a 
valve having a narrow aperture. Disso cube technology was developed by Muller et al. in 
which, the suspension of the drug is made to pass through a small orifice that results in a 
reduction of the static pressure below the boiling pressure of water, which leads to boiling 
of water and formation of gas bubbles. When the suspension leaves the gap and normal 
air pressure is reached again, the bubbles shrink and the surrounding part containing the 
drug particles rushes to the center and in the process colloids, causing a reduction in the 
particle size. Most of the cases require multiple passes or cycles through the 
homogenizer, which depends on the hardness of drug, the desired mean particle size and 
the required homogeneity. 
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Scholer et al, prepared atovaquone nanosuspensions using this technique [27]. To 
produce a Nanosuspension with a higher concentration of solids, it is preferred to start 
homogenization with very fine drug particles, which can be accomplished by pre-milling. 
Media milling (NanoCrystals): 
This patent-protected technology was developed by Liversidge et al. (1992). 
Formerly, the technology was owned by the company nanosystems but recently it has 
been acquired by Élan Drug Delivery. In this method, the nanosuspensions are produced 
using high-shear media mills or pearl mills. The media mill consists of a milling chamber, 
a milling shaft and a recirculation chamber (Figure 9). The milling chamber charged with 
polymeric media is the active component of the mill. The mill can be operated in a batch 
or recirculation mode. Crude slurry consisting of drug, water and stabilizer is fed into the 
milling chamber and processed into nano-crystalline dispersion and the milling media or 
pearls are then rotated at a very high shear rate. The milling process is performed under 
controlled temperatures. The typical residence time generated for a nanometer-sized 
dispersion with a mean diameter of <200nm is 30–60 min [23]. 
Principle
 [23]
: 
The high energy and shear forces generated as a result of the impaction of the 
milling media with the drug provide the energy input to break the microparticulate drug 
into nano-sized particles. The milling medium is composed of glass, zirconium oxide or 
highly cross-linked polystyrene resin. The process can be performed in either batch or 
recirculation mode. In batch mode, the time required to obtain dispersions with uni-modal 
distribution profiles and mean diameters <200 nm is 30–60 min. The media milling 
process can successfully process micronized and non-micronized drug crystals. Once the 
formulation and the process are optimized, very little batch-to-batch variation is observed 
in the quality of the dispersion. 
Advantages: 
 Drugs that are poorly soluble in both aqueous and organic media can be easily 
formulated into nanosuspensions.  Ease of scale-up and little batch-to-batch variation.  Narrow size distribution of the final nano-sized product. 
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 Flexibility in handling the drug quantity, ranging from 1 to 400mg/ml, enabling 
formulation of very dilutes as well as highly concentrated nanosuspensions. 
A comparison of the size of naproxen crystals before and after media milling. 
Limitations: 
The major concern is the generation of residues of milling media, which may be 
introduced in the final product as a result of erosion. This could be problematic when 
Nanosuspensions are intended to be administered for a chronic therapy. The severity of 
this problem has been reduced to a great extent with the advent of polystyrene resin-based 
milling medium. For this medium, residual monomers are typically 50 ppb and the 
residuals generated during the milling processing are not more than 0.005% w/w of the 
final product or the resulting solid dosage form. 
Homogenization in non-aqueous media (Nanopure): 
Nanopure is suspensions homogenized in water free media or water mixtures i.e. 
the drug suspensions in the non- aqueous media were homogenized at 0º C or even below 
the freezing point and hence are called "deep-freeze" homogenization. The results 
obtained were comparable to Disso cubes and hence can be used effectively for 
thermolabile substances at milder conditions. The Nanocrystals of the drug dispersed in 
liquid polyethylene glycol (PEG) or various oils can be directly filled as drug suspensions 
into HPMC capsules or gelatin. 
Advantages: 
 The dispersion medium need not be removed.  Evaporation is faster and under milder conditions (when water and water miscible 
liquids are used).  This is useful for temperature sensitive drugs.  For i.v. injections, isotonic nanosuspensions are obtained by homogenizing in 
water-glycerol mixtures [22]. 
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Combined precipitation and homogenization (Nanoedge): 
 The drug is dissolved in an organic solvent and this solution is mixed with a 
miscible anti-solvent for precipitation. In the water-solvent mixture, the solubility is low 
and the drug precipitates. Precipitation has also been coupled with high shear processing. 
This is accomplished by a combination of rapid precipitation and high-pressure 
homogenization. The nanoedge patented technology by Baxter depends on the 
precipitation of friable materials for fragmentation under conditions of high shear and/or 
thermal energy. Rapid addition of a drug solution to an anti-solvent leads to sudden super 
saturation of the mixed solution, and generation of fine crystalline or amorphous solids. 
Precipitation of an amorphous material may be favored at high super saturation when the 
solubility of the amorphous state is exceeded [28]. 
 
 
The basic principles of nanoedge are the same as that of precipitation and 
homogenization. A combination of these techniques results in smaller particle size and 
better stability in a shorter time. The major drawback of the precipitation technique, such 
as crystal growth and long-term stability, can be resolved using the Nanoedge technology 
[20] 
Nanojet Technology: 
This technique, called ‘opposite stream or nanojet technology’, uses a chamber 
where a stream of suspension is divided into two or more parts, which colloid with each 
other at high pressure upto 4000 bar at the high velocity of 1000m/s[29]. The high shear 
force produced during the process results in particle size reduction. Equipment using this 
principle includes the M110L and M110S microfluidizers (Microfluidics). Dearn 
prepared nanosuspensions of atovaquone using the microfluidization process. The major 
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limitation of this technique is the high number of passes through the microfluidizers (up 
to 75 passes) and that the product obtained contains a relatively larger fraction of 
microparticles [20]. A limitation of this process is the large production time [29]. 
Emulsification-solvent evaporation technique: 
This technique involves preparing a solution of drug followed by its emulsification in 
another liquid that is a non-solvent for the drug. Evaporation of the solvent leads to 
precipitation of the drug. Crystal growth and particle aggregation can be controlled by 
creating high shear forces using a high-speed stirrer [22]. 
Supercritical fluid method: 
Supercritical fluid technology can be used to produce nanoparticle from drug 
solutions. The various methods attempted are rapid expansion of supercritical solution 
process (RESS), supercritical anti-solvent process and precipitation with compressed anti-
solvent process (PCA). The RESS involves expansion of the drug solution in supercritical 
fluid through a nozzle, which leads to loss of solvent power of the supercritical fluid 
resulting in precipitation of the drug as fine particles. In the PCA method, the drug 
solution is atomized into a chamber containing compressed CO2. As the solvent is 
removed, the solution gets supersaturated and thus precipitates as fine crystals. The 
supercritical anti- solvent process uses a supercritical fluid in which a drug is poorly 
soluble and a solvent for the drug that is also miscible with the supercritical fluid. The 
drug solution is injected into the supercritical fluid and the solvent gets extracted by the 
supercritical fluid and the drug solution gets supersaturated. The drug is then precipitated 
as fine crystals [22]. 
Limitations: 
 Use of hazardous solvents and use of high proportions of surfactants and 
stabilizers as compared with other techniques.   Particle nucleation overgrowth due to transient high supersaturation, which may 
also result in the development of an amorphous form or another undesired 
polymorph.  
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Dry co-grinding: 
 
Nanosuspensions prepared by high pressure homogenization and media milling 
using pearl-ball mill are wet–grinding processes. Recently, nanosuspensions can be 
obtained by dry milling techniques. Successful work in preparing stable nanosuspensions 
using dry-grinding of poorly soluble drugs with soluble polymers and copolymers after 
dispersing in a liquid media has been reported. Itohet al. reported the colloidal particles 
formation of many poorly water soluble drugs; griseofulvin, glibenclamide and nifedipine 
obtained by grinding with polyvinyl pyrrolidone (PVP) and Sodium dodecyl sulfate 
(SDS). Many soluble polymers and co-polymers such as PVP, Polyethylene glycol 
(PEG), Hydroxypropyl methylcellulose (HPMC) and cyclodextrin derivatives have been 
used. Physicochemical properties and dissolution of poorly water soluble drugs were 
improved by co-grinding because of an improvement in the surface polarity and 
transformation from a crystalline to an amorphous drug. Recently, nanosuspensions can 
be obtained by dry milling techniques. Dry co-grinding can be carried out easily and 
economically and can be conducted without organic solvents. The co-grinding technique 
can reduce particles to the submicron level and a stable amorphous solid can be obtained 
[30]. 
Emulsion as template
 [23]
: 
Apart from the use of emulsions as a drug delivery vehicle, they can also be used 
as templates to produce nanosuspensions. The use of emulsions as templates is applicable 
for those drugs that are soluble in either volatile organic solvent or partially water-
miscible solvent. Such solvents can be used as the dispersed phase of the emulsion. There 
are two ways of fabricating drug nanosuspensions by the emulsification method. In the 
first method, an organic solvent or mixture of solvents loaded with the drug is dispersed 
in the aqueous phase containing suitable surfactants to form an emulsion. The organic 
phase is then evaporated under reduced pressure so that the drug particles precipitate 
instantaneously to form a nanosuspensions stabilized by surfactants. Since one particle is 
formed in each emulsion droplet, it is possible to control the particle size of the 
nanosuspensions by controlling the size of the emulsion. Optimizing the surfactant 
composition increases the intake of organic phase and ultimately the drug loading in the 
emulsion. Originally, organic solvents such as methylene chloride and chloroform were 
used. However, environmental hazards and human safety concerns about residual solvents 
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have limited their use in routine manufacturing processes. Relatively safer solvents such 
as ethyl acetate and ethyl formate can still be considered for use.  
Another method makes use of partially water-miscible solvents such as butyl 
lactate, benzyl alcohol and triacetin as the dispersed phase instead of hazardous solvents. 
The emulsion is formed by the conventional method and the drug nanosuspension is 
obtained by just diluting the emulsion. Dilution of the emulsion with water causes 
complete diffusion of the internal phase into the external phase, leading to instantaneous 
formation of a nanosuspension. The nanosuspension thus formed has to be made free of 
the internal phase and surfactants by means of di-ultrafiltration in order to make it 
suitable for administration. 
However, if all the ingredients that are used for the production of the 
nanosuspensions are present in a concentration acceptable for the desired route of 
administration, then simple centrifugation or ultracentrifugation is sufficient to separate 
the nanosuspensions. 
Advantages: 
 Use of specialized equipment is not necessary.   Particle size can easily be controlled by controlling the size of the emulsion droplet.   Ease of scale-up if formulation is optimized properly. 
Limitations:  Drugs that are poorly soluble in both aqueous and organic media cannot be 
formulated by this technique.   Safety concerns because of the use of hazardous solvents in the process.   Need for di-ultrafiltration for purification of the drug nanosuspensions, which may 
render the process costly.   High amount of surfactant/stabilizer is required as compared to the production 
techniques described earlier.   The production of drug nanosuspensions from emulsion templates has been 
successfully applied to the poorly water-soluble and poorly bioavailable anti-
cancer drug mitotane, where a significant improvement in the dissolution rate of 
the drug (five-fold increase) as compared to the commercial product was 
observed.  
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Microemulsion as template/Lipid emulsion
 [23]
: 
 
Microemulsions are thermodynamically stable and isotropically clear dispersions 
of two immiscible liquids, such as oil and water, stabilized by an interfacial film of 
surfactant and co-surfactant. Their advantages, such as high drug solubilization, long 
shelf-life and ease of manufacture, make them an ideal drug delivery vehicle. Taking 
advantage of the microemulsion structure, one can use microemulsions even for the 
production of nanosuspensions. Oil-in-water microemulsions are preferred for this 
purpose. The internal phase of these microemulsions could be either a partially miscible 
liquid or a suitable organic solvent, as described earlier. The drug can be either loaded in 
the internal phase or pre-formed microemulsions can be saturated with the drug by 
intimate mixing. The suitable dilution of the microemulsion yields the drug 
nanosuspensions by the mechanism described earlier. The influence of the amount and 
ratio of surfactant to co-surfactant on the uptake of internal phase and on the globule size 
of the microemulsion should be investigated and optimized in order to achieve the desired 
drug loading. The nanosuspension thus formed has to be made free of the internal phase 
and surfactants by means of di-ultrafiltration in order to make it suitable for 
administration. However, if all the ingredients that are used for the production of the 
nanosuspensions are present in a concentration acceptable for the desired route of 
administration, then simple centrifugation or ultracentrifugation is sufficient to separate 
the nanosuspensions.  
 
The advantages and limitations are the same as for emulsion templates. The only 
added advantage is the need for less energy input for the production of nanosuspensions 
by virtue of microemulsions. Also the limitation will include large amounts of surfactant 
or stabilizers are required [31]. E.g. Griseofulvin nanosuspensions which is prepared by 
using water, butyl lactate, lecithin and the sodium salt of tauro-deoxycholate, where a 
significant improvement in the dissolution rate of the drug (three-fold increase) as 
compared to the commercial product was observed. It was found that the nature of the co-
surfactant affected the dissolution rate of the drug nanosuspensions, as anticipated. 
However, this technique is still in its infancy and needs more thorough investigation. For 
a comparative advantages & limitations with examples, see table 6. 
 
 
32 
 
Table 6: Advantages and disadvantages of various preparation techniques of 
nanosuspensions 
[28] 
Method  Advantages  Limitations  Drug  
High-pressure 
Homogenization 
 
 
Widely applying 
regions, ease of 
scale-up and little 
batch to batch 
variation, narrow 
size distribution in the 
final product, 
allowing aseptic 
production of 
nanosuspensions for 
parenteral 
administration and 
flexibility in handling 
the drug quantity.  
Pretreatment of 
micronized drug 
particles and pre-
suspending 
materials  
Before subjecting it 
to homogenization. 
Albendazole. 
Amphotericin B.  
Aphidicolin. 
Atovaquone. 
Azithromycin.  
Bupravaquone. 
Clofazamine. 
Fenofibrate. 
Glucocorticoid 
drugs.  
Milling 
Same as those for 
high-pressure 
homogenization. 
Potential erosion of 
material from the 
milling pearls. 
Cilostazol. 
Danazol. 
Naproxen. 
Microprecipitation 
Low need of energy, 
stable products and 
simple process. 
 
Narrowly applying 
space, wide size 
distribution and 
potential toxicity of 
non-aqueous 
solvents.  
Breviscapine. 
Griseofulvin. 
Ibuprofen.  
Mitotane. 
 
Emulsion and 
microemulsion 
 
Low need of energy, 
stable products, 
simple process, small 
size of particles and 
uniform particle 
distribution.  
High concentration 
undesired 
surfactants and 
residual solvents.  
 
      ___  
Dry Co-grinding
[21]
 
Easy process No 
organic solvent 
Require short 
grinding time 
Generation of 
residue of milling 
media  
Clarithromycin. 
Glibenclamide. 
Glisentide. 
Griseofulvin. 
Naproxen.  
Nifedipine. 
Phenytoin. 
Pranlukast. 
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Figure 5: Various methods for preparation of nanosuspensions
 [22].
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Pharmaceutical application of nanosuspensions
 [27]
: 
Intravenous administration: 
             The parenteral route of administration provides a quick onset of action, rapid 
targeting and reduced dosage of the drug. It is the preferred route for drugs undergoing 
first-pass metabolism and those that are not absorbed in the GIT or degraded in the GIT. 
One of the important applications of nanosuspensions technology is the formulation of 
intravenously administered products. IV administration results in several advantages, 
such as administration of poorly soluble drugs without using a higher concentration of 
toxic co solvents, improving the therapeutic effect of the drug available as conventional 
oral formulations and targeting the drug to macrophages and the pathogenic 
microorganisms residing in the macrophages. 
Bioavailability enhancement: 
 The poor oral bioavailability of the drug may be due to poor solubility, poor 
permeability or poor stability in the gastrointestinal tract (GIT).Nanosuspensions resolve 
the problem of poor bioavailability by solving the twin problems of poor solubility and 
poor permeability across the membrane. Bioavailability of poorly soluble oleanolic acid, 
a hepato protective agent, was improved using a Nanosuspensions formulation. The 
therapeutic effect was significantly enhanced, which indicated higher bioavailability. This 
was due to the faster dissolution (90% in 20 min) of the lyophilized Nanosuspensions 
powder when compared with the dissolution from a coarse powder (15% in 20 min). 
Pulmonary administration: 
Aqueous Nanosuspensions can be nebulized using mechanical or ultrasonic nebulizers 
for lung delivery. Because of their small size, it is likely that in each aerosol droplet at 
least one drug particle is contained, leading to a more uniform distribution of the drug in 
lungs. They also increase adhesiveness and thus cause a prolonged residence time. 
Budenoside drug nanoparticles were successfully nebulized using an ultrasonic nebulizer. 
 Ocular administration: 
Ocular delivery of the drugs as nanosuspensions to provides a sustained release of 
drug. Pignatello et al. prepared Eudragit retard nanosuspensions of cloricromene for 
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ocular delivery. They observed that the drug showed a higher availability in rabbit 
aqueous humor and the formulation appeared to offer a promising means of improving 
the shelf-life and the bioavailability of this drug after ophthalmic application. 
Drug targeting: 
Nanosuspensions can also be used for targeting as their surface properties and 
changing of the stabilizer can easily alter the in-vivo behavior. The drug will be up taken 
by the mononuclear phagocytic system to allow regional-specific delivery. This can be 
used for targeting anti-myco bacterial, fungal or leish manial drugs to the macrophages if 
the infectious pathogen is persisting intracellularly. 
Mucoadhesion of the nanoparticles: 
Nanoparticles orally administered in the form of a suspension diffuse into the 
liquid media and rapidly encounter the mucosal surface. The particles are immobilized at 
the intestinal surface by an adhesion mechanism referred to as "bioadhesion." From this 
moment on, the concentrated suspension acts as a reservoir of particles and an adsorption 
process takes place very rapidly. The direct contact of the particles with the intestinal 
cells through a bioadhesive phase is the first step before particle absorption. The 
adhesiveness of the nanosuspensions not only helps to improve bioavailability but also 
improves targeting of the parasites persisting in the GIT. 
Targeted drug delivery: 
The need to target drugs to specific sites is increasing day by day as a result of 
therapeutic and economic factors. Nanoparticulate systems have shown tremendous 
potential in targeted drug delivery, especially to the brain. Successful targeting of the 
peptide dalarg in to the brain by employing surface modified poly isobutl cyanoacrylate 
nanoparticles has been a major achievement in targeted delivery. Likewise 
nanosuspensions can be used for targeted delivery as their surface properties and in-vivo 
behavior can easily be altered by changing either the stabilizer or the milieu. Their 
versatility and ease of scale-up and commercial production enables the development of 
commercially viable nanosuspensions for targeted delivery. Overall nanosuspensions 
have indicated a good potential in targeted drug delivery but this has yet to be fulfilled. 
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Oral drug delivery: 
Oral drug delivery is the quick onset of action, which is seen in case of naproxen, an 
NSAID.  In spite of the tremendous potential of nanosuspensions in oral delivery, 
formulating compounds as nano-crystalline dispersions is not of value when metabolic 
and/or permeation-related issues affect bioavailability. However, in future, it should be 
possible to engineer nanosuspensions by using the agents that enhance permeation and/or 
minimize gut-related metabolic issues. This amalgamated approach would facilitate 
delivery of the compounds belonging to BCS Class IV that exhibit poor water solubility 
and poor membrane permeability. 
Characterisation of nanosuspensions
 [27]
: 
Nanosuspensions are characterized for appearance, color, odor, assay, related 
impurities, particle size, zeta potential, crystalline status, dissolution studies and in- vivo 
studies. Among this, the most important characterization techniques were discussed 
(Figure 11) [31]. 
Mean particle size and size distribution: 
The mean particle size and the span of particle size distribution (polydispersity index, 
PI) are two important characteristic parameters because they affect the saturation 
solubility, dissolution rate, physical stability, even in-vivo behaviour of nanosuspensions. 
It is indicated that saturation solubility and dissolution velocity show considerable 
variation with the changing, particle size of the drug. Particle size distribution determines 
the physiochemical behaviour of the formulation, such as saturation solubility, dissolution 
velocity and physical stability. The particle size distribution can be determined by photon 
correlation spectroscopy (PCS), laser diffraction (LD) and coulter counter multisizer. PCS 
can even be used for determining the width of the particle size distribution (polydispersity 
index, PI). The PI is an important parameter that governs the physical stability of 
nanosuspensions and should be as low as possible for the long-term stability of 
nanosuspensions. A PI value of 0.1– 0.25 indicates a fairly narrow size distribution 
whereas a PI value greater than 0.5 indicates a very broad distribution. The coulter-
counter gives the absolute number of particles per volume unit for the different size 
classes, and it is a more efficient and appropriate technique than LD for quantifying the 
contamination of nanosuspensions by microparticulate drugs. 
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Surface charge (zeta potential): 
Zeta potential gives certain information about the surface charge properties and 
further the long-term physical stability of the nanosuspensions. The zeta potential of a 
nanosuspension is governed by both the stabilizer and the drug itself. For a stable 
suspension stabilized only by electrostatic repulsion, a minimum zeta potential of ±30 
mV is required whereas in case of a combined electrostatic and steric stabilizer, a zeta 
potential of ±20 mV would be sufficient. 
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Crystalline state and particle morphology: 
The assessment of the crystalline state and particle morphology together helps in 
understanding the polymorphic or morphological changes that a drug might undergo 
when subjected to nanosizing. Nanosuspensions can undergo a change in the crystalline 
structure, which may be to an amorphous form or to other polymorphic forms because of 
high-pressure homogenization. The changes in the solid state of the drug particles as well 
as the extent of the amorphous fraction can be determined by X-ray diffraction analysis 
and supplemented by differential scanning calorimetry. In order to get an actual idea of 
particle morphology, scanning electron microscopy is preferred. 
Saturation solubility and dissolution velocity: 
Nanosuspensions have an important advantage over other techniques, that it can 
increase the dissolution velocity as well as the saturation solubility. The saturation 
solubility of the drug in different physiological buffers as well as at different temperatures 
should be assessed using methods described in the literature. The investigation of the 
dissolution velocity of nanosuspensions reflects the advantages that can be achieved over 
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conventional formulations, especially when designing the sustained-release dosage forms 
based on nanoparticulate drugs. 
Dissolution Studies: 
An USP dissolution apparatus (Electro lab, India) Type II (paddle method) at rotation 
speed of 50 rpm was used for in vitro testing of drug dissolution from the various 
formulations obtained after each size reduction step. 
Stability of nanosuspensions: 
The high surface energy of nanosized particles induces agglomeration of the drug 
crystals. The main function of the stabilizer is to wet the drug particles thoroughly to 
prevent Ostwald ripening and agglomeration of the nanosuspensions and form a 
physically stable formulation by providing a steric or an ionic barrier. Typical examples 
of stabilizers used in nanosuspensions are cellulosics, Poloxamer, Polysorbates, lecithin, 
polyoleate and povidone. Lecithin may be preferred in developing parenteral 
nanosuspensions. 
Drug content: 
Drug content of nanosuspensions formulation can be carried out by extracting the 
nanosuspensions in suitable solvent mixture, like methanol: THF (1:1) mixture, shaken 
well, and then centrifuged. The supernatants can be separated and diluted with same 
solvent mixture and the absorbance can be measured at suitable Ȝmax. The drug content 
then can be calculated using the calibration curve [21]. 
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 2.4. REVIEW OF PREVIOUS WORKS 
Mullar RH et al., reported nanosuspensions contain submicron colloidal dispersion of 
particles in liquid phase stabilized by surfactants and the reduction of drug particles into 
submicron range leads to significant increase in the dissolution rate and enhanced 
bioavailability [32].  
Ali HS et al. prepared Nanosuspensions by two technologies such as top-down and 
bottom-up technology. In the “top-down” technology, mechanical comminution process is 
involved where   larger drug particles are reduced to smaller size as in milling (jet mills and 
pear-ball mills) and homogenization (high pressure homogenizers). In the “bottom-up” 
technology, molecules are dissolved and then precipitated by non-solvent addition as in 
supercritical fluid technology, spray freezing into liquid process, evaporative precipitation in 
to aqueous solutions and liquid solvent change process. Although “top down” approaches are 
widely employed, the drawbacks associated with mechanical attrition processes such as time 
consumption, intensive energy use, introduction of impurities, inadequate control of particles 
size and electrostatic effects, promote greater interest towards “bottom up” preparation of 
Nanoparticles[33]. 
 Kristl J et al., Due to low water solubility Nanosuspensions of Celecoxib was 
investigated. Emulsion-diffusion technique was used to formulate the Nanosuspensions. 
Celecoxib dissolved in ethyl acetate was added to aqueous solution of stabilizers (Tween 80 
and a combination of PVP K-30) and homogenized [34]. 
 Pignatello R et al., prepared Cloricromene (AD6) loaded polymeric Nanoparticle 
suspensions for ophthalmic application using inert polymer resins (Eudragit RS100 and 
RL100) by quasi emulsion solvent diffusion technique by varying some formulation 
parameters. These AD6 loaded Nanosuspensions showed improved shelf life and 
bioavailability of drug after ophthalmic application [35]. 
 Fadda AM et al., Diclofenac is a potent nonsteroidal anti-inflammatory drug with a 
very low aqueous solubility and gastrolesive actions. To improve dissolution profile and oral 
bioavailability of Diclofenac, Diclofenac Nanosuspensions were formulated by 
homogenization technique and results showed that drug dissolution rate in Nanosuspensions 
was highly enhanced [36]. 
42 
 
Mullar RH et al., Bupravaquone is a new naphthoquinone antibiotic used in the 
treatment of Cryptosporodiumparvum infection. The bioavailability of Bupravaquone is 
limited through oral administration so to overcome the problem of high elimination rate 
caused by diarrhoea, Bupravaquone was formulated as a mucoadhesive Nanosuspensions by 
high pressure homogenization [37]. 
Zhonggui H et al., 10-hydroxycamptothecin is a potent antitumor agent, has poor 
solubility in water and organic solvents and it was found that  lactone ring readily open and 
converted to carboxylate form under physiologic and alkaline condition. So it was prepared 
as Nanosuspensions with active form of 10-hydroxycamptothecin by microprecipitation, high 
pressure homogenisation method [38]. 
Agnihotri SM et al., reported Polymeric Nanoparticles suspensions were prepared 
from poly (lactide-co-glycolide) and poly (lactide-co-glycolide-leucine) {poly [Lac (Glc-
Leu)]} biodegradable polymers and loaded with Diclofenac sodium to improve the ocular 
availability of the drug. Nanoparticle suspensions were prepared by emulsion and solvent 
evaporation technique and system showed a better size distribution for ophthalmic 
application. In vitro release tests showed an extended-release profile of Diclofenac sodium 
from the Nanoparticles suspensions [39]. 
 Jin S et al., identified Nanosuspensions as the most promising delivery system for 
poorly soluble drugs due to improved bioavailability, high drug loading, and targeting 
capability. Used different manufacturing processes including solidification and solid 
modification technique for the production of Nanosuspensions [40]. 
Arunkumar N et al., Atorvastatin calcium is used in the treatment of 
hypercholesterolemia. Because of low solubility of Atorvastatin crystals it is formulated as 
Nanosuspensions by high pressure homogenization technique in which the crystalline form is 
converted to amorphous form which showed significant increase in solubility [41]. 
 Zhang D et al., Azithromycin is clinically effective against Gram-positive and Gram-
negative bacteria. Because of low bioavailability, Azithromycin was prepared as 
Nanosuspensions by high pressure homogenization to increase its saturation solubility and 
dissolution velocity. In order to enhance the stability of the Nanosuspensions, it was 
converted to freeze-dried powder by lyophilization [42]. 
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Hongyu P et al., reported solid-in-oil Nanosuspensions as a potent carrier of 
Diclofenac sodium for enhancing percutaneous absorption by Transdermal delivery [43]. 
Akanksha T et al., described Nanosuspensions as effective treatment of ocular 
diseases by improving bioavailability16. 
Thakar Det al developed and characterized the Nanosuspensions of telmisartan by 
bead milling process. In this study, the media used is ZnO2 beads. A variety of surface active 
agents were tested for their stabilizing effects. Formulation factors evaluated were ratio of 
polymer to drug, whereas process parameters were milling time and concentration of ZnO2 
beads. Responses measured in this study include particle size, measurement, particle size 
distribution and zeta potential [44]. 
 HecqJ and Co-Workers reported Nanosuspensions of poorly water-soluble drugs 
such as Nifedipine (20g/ml). In order to enhance these characteristics, preparation of 
Nifedipine Nanoparticles has been achieved using high pressure homogenization. Through 
the DSC and XRD study, it has been shown that initial crystalline state is maintained 
following particle size reduction and that the dissolution characteristics of Nifedipine 
Nanoparticles were significantly increased in regards to the commercial product. These 
approaches have a general applicability to many poorly water-soluble drug entities [45]. 
RuolenXiong and Co-Workers prepared injectable nimodipine Nanosuspensions by 
high-pressure homogenization. Characterization of the product was performed for SEM and 
DSC. Irritability study in rabbits showed that this formulation provided less local irritation 
and phlebitis risks than the commercial ethanol product, which represented a promising new 
drug formulation for intravenous therapy of subarachnoid hemorrhage related vasospasm [46]. 
Pandya M Vikramet al formulated and characterized Nanosuspensions of simvastatin 
using pluronic F127 and ZnO2 beads by wet milling technique. The results showed that 
Nanosuspensions prepared with the higher concentration of pluronic F127 and the higher 
quantities of ZnO2 reduce the particle size and enhanced the dissolution rate of the 
formulation. This preparation of simvastatin nanosuspensions increased bioavailability, 
dissolution rate, solubility [47]. 
Thakar D et al developed and characterized the Nanosuspensions of telmisartan by 
bead milling process. In this study, the media used is ZnO2 beads. A variety of surface active 
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agents were tested for their stabilizing effects. Formulation factors evaluated were ratio of 
polymer to drug, whereas process parameters were milling time and concentration of ZnO2 
beads. Responses measured in this study include particle size, measurement, particle size 
distribution and zeta potential [48]. 
 ChetanDetroja et al enhanced the oral bioavailability of practically insoluble 
candesartan cilexetil by preparing Nanosuspensions using ZnO2 beads and converted to solid 
state by spray drying. DSC and XRD analysis showed that crystalline state of CC remained 
unchanged in SDCN. Dissolution studies in phosphate buffer pH 6.5 containing 0.7% Tween 
20 showed SDCN was almost completely dissolved exhibiting higher dissolution velocity and 
solubility. In-vivo performance, showed increase in dissolution velocity and saturation 
solubility leads to enhancement of bioavailability of SDCN when compared to bulk 
candersartancilexetil suspension. Thus, the results conclusively demonstrated a significant 
enhancement in antihypertensive activity of candesartan when formulated as 
Nanosuspensions [49]. 
HetalParesh et al developed Nanosuspensions of olmesartan medoxomil using                      
media milling technique. The results indicated that the initial crystalline state is preserved 
following particle size reduction and that the saturation solubility, dissolution velocity and 
diffusion rate of the drug from the Nanosuspensions is significantly higher than that of the 
plain drug suspension as well as from the marketed tablet formulation[50]. 
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3. AIM AND OBJECTIVE 
The aim of this work is to formulate and develop nanosuspensions containing a    
hypercholesterolemia drug and carrier’s urea, PVP γ0, ȕ-cyclodextrin and Tween 80 & 
SLS. 
Objective of the Study: 
 The main objective of the present study is to carry out formulation and evaluation 
of nanosuspensions of hypercholesterolemia by using suitable polymers to improve its 
bioavailability. 
The objectives of the present study as follows 
 Preformulation studies for selection of suitable excipients to develop the 
dosage form based on physicochemical properties of drug and excipients.  Screening of excipients for compatibility and efficacy for developing the 
formulation.  Carry out Preformulation study of Pitavastatin drug.  Preparation of nanosuspensions drug delivery system for enhancing the 
solubility and thus bioavailability of drug.  Evaluation of nanosuspensions drug delivery system, in vitro.  Optimize the formulation using experimental design technique regarding 
particle size,  particle size distribution, zeta potential, stability, release profile, 
etc.  Evaluation of formulated product and identification of defects.  Study the stability of the formulation following ICH guidelines. 
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The following parameters were examined: 
1. Pre-formulation studies. 
 a) Drug and carrier interaction by FT-IR spectroscopy. 
 b) Drug and carrier interaction by Differential Scanning Calorimetry (DSC) 
2. Preparation of standard curve of Pitavastatin in 0.1N HCL Buffer 
3. Preparation of Pitavastatin Nanosuspensions by precipitation method. 
4. Evaluation of Pitavastatin Nanosuspensions. 
a) Drug and carrier interaction by FT-IR spectroscopy. 
b) Particle size determination by Scanning Electron Microscopy (SEM) 
c) Surface characteristic by Zeta potential analyzer. 
d) Thermal analysis by Differential Scanning Calorimetry (DSC). 
e) In-vitro dissolution studies 
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5. PROFILES 
5.1. DRUG PROFILE 
5.1.1. LIVALO (Pitavastatin): 
Category   : Hypercholesterolemia 
 
Empirical formula  : C50H46CaF2N2O8 
 
Molecular weight  : 880.98. 
 
Physical properties  : Odorless and occurs as white to pale-yellow powder. 
 
Solubility: 
It is freely soluble in pyridine, chloroform, dilute hydrochloric acid, and 
tetrahydrofuran, soluble in ethylene glycol, sparingly soluble in octanol, slightly soluble 
in methanol, very slightly soluble in water or ethanol, and practically insoluble in 
acetonitrile or diethyl ether. 
Chemical structure: 
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Chemical name: 
Pitavastatin is (+) monocalcium bis {(3R, 5S, 6E)-7-[2-cyclopropyl-4-(4-
fluorophenyl)-3-quinolyl]-3, 5dihydroxy-6-heptenoate}. 
Mechanism of action: 
Pitavastatin is lipid-lowering agent that works to control the synthesis of cholesterol 
via competitive inhibition of the liver enzyme, 3-hydroxy-3-methylglutaryl coenzyme A 
(HMG-CoA) reductase. As a result, a compensatory increase in LDL-receptor expression 
can be observed which facilitates an increase LDL catabolism. 
Pharmacokinetics: 
Absorption  : Pitavastatin was absorbed in the small intestine but very little in  
                                     the colon. 
Distribution  : 148 L 
Protein binding : >99% protein bound in human plasma, mainly to albumin and  
                                       alpha 1-acid glycoprotein. 
Metabolism: 
Pitavastatin is mainly metabolized by liver. It undergoes glucuronidation by uridine 5-
diphosphate glucuronosyl transferases (UGT1A3 and UGT2B7) to form the major 
circulating metabolite, pitavastatin lactone. The cytochrome P450 system has little 
involvement with the metabolism of pitavastatin. There is some metabolism by CYP2C9 
and to a lesser extent, CYP2C8. Studies suggest that concomitant therapy with drugs that 
are involved with the cytochrome P450 system will not affect the pharmacokinetics of 
pitavastatin. 
Route of elimination : 79% in feces and 15% excreted in urine. 
Bioavailability :  51%; 
Half-life elimination : Plasma elimination half-life = 12 hours. 
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Clearance: CL/F (apparent clearance), 4 mg, healthy male Korean subjects = 23.6 L/h. 
Adverse reactions: Toxicity the most frequent adverse reactions (rate ≥β.0% in at least 
one marketed dose) were myalgia, back pain, diarrhea, constipation and pain in extremity. 
                                          5.2. POLYSORBATE 80 
Synonyms
82: Atlas E, Aarmotan PMS 20, capmul POE-O, cremophor PS-80, crillet4, 
crillet 50, Emrite 6120 & Tween 80 
Chemical structure: 
 
 
 
Description: Yellow oily liquid with characteristic odour and a warm and somewhat 
bitter taste. 
Functional category: Dispersing agents, emulsifying agent, non ionic surfactant, 
solubilizing agent, suspending agent & wetting agent 
Typical properties: 
HLB value  : 15 
Solubility  : Soluble in ethanol and water 
51 
 
Specific gravity : 1.08 
Acidity/ alkalinity : PH=6-8 for a aqueous solution 
Flash point  : 1490c 
Viscosity  : 425mPaS 
Incompatibilities: Discoloration or precipitation occurs with various substances, 
especially phenols, tannins, tars and tar like materials. The anti microbial activity of 
parabens is reduced in the presence of Polysorbates. 
Stability and storage conditions: 
 Polysorbates are stable to electrolytes and weak acids and bases; gradual 
saponification occurs with strong acids and bases .Polysorbates is hygroscopic and also 
prolonged storage can lead to the formation of peroxides. Polysorbates can be stored in a 
well closed container, protected from light in a cool, dry place. 
Safety: Polysorbates are used in oral, parenteral and topical formulations and generally 
regarded as non-toxic and non- irritant materials. There are however cases of 
hypersensitivity following their topical and intramuscular use when heated to 
decomposition, the Polysorbates emit acrid smoke and irritating fumes. 
Moderately toxic by IV route: Mildly toxic by ingestion. 
Applications: 
 1. Widely useful as emulsifying agents in the preparation of stable oil in water 
pharmaceutical emulsions. 
2. Also useful as solubilizing agents for a variety of substances including essential oils 
and oils soluble vitamins. 
3. They can be used as wetting agents in the formulation of oral and parenteral 
formulations. 
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4. They have been found to be useful in improving the oral bio availability of drug 
molecules that are substrates for the p-glycol protein. 
                                                     
                                                               
                                                            5.3. UREA 
Synonyms:URE;UREA;UREUM;B-I-K;Hyanit;UreaAr;UreaGr;UreaBp;UreaIp;Panafil 
 
Chemical structure: 
 
                                       
Description: A compound formed in the liver from ammonia produced by the 
deamination of amino acids. It is the principal end product of protein catabolism and 
constitutes about one half of the total urinary solids. 
Chemical Formula  : CH4N2O 
Formula Weight  : 60.06 
Solubility   : H2O: 8 M at 20 °C 
Pharmacodynamic: As humectants, urea draws water into the striatum corneum. 
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                            5.4. Polyvinylpyrrolidone 
Synonym: Poly [1-(2-oxo-1-pyrrolidinyl) ethylene]; polyvidone; Polyvinylpyrrolidone; 
PVP; 1-vinyl-2-pyrrolidinone polymer 
Chemical name        :      1-Ethenyl-2-pyrrolidinone homo polymer. 
Empirical Formula  :  (C6H9NO) n 
Molecular Weight  :   2500-3000. 
Structural Formula: 
 
 
 
Description:    povidone occurs as a fine, white to creamy-white colored, odorless. 
Typical properties 
Acidity/alkalinity  :    pH=3.0-7.0(5%w/v aqueous solution). 
Flow ability   :    20g/s for povidone k-15; 
                                         1620g/s for povidone k-29/32. 
Melting point   :    Softens at 1500c. 
Moisture content: 
Povidone is very hygroscopic, significant amounts of moisture being absorbed at 
low relative humidities. 
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Solubility: 
Freely soluble in acids, chloroform, ethanol (95%), ketones, methanol, and water; 
practically insoluble in ether hydrocarbons, and mineral oil. In water, the concentration of 
a solution is limited only by the viscosity of the resulting solution, which is a function of 
the polymer. 
Viscosity (dynamic): The viscosity of aqueous povidone solutions depends on both the 
concentration and    the molecular weight of the polymer employed. 
Functional Category: Disintegrent; dissolution aid; suspending agent; tablet binder 
Applications:                                                                                     
It is used as a binder in many pharmaceutical tablets it simply through the body when 
taken orally. 
 It is used in pleurodesis.  It is used as an adhesive in glue stick and hot-melt adhesive.  As an emulsifier and Disintegrent for solution polymerization   Used in aqueous metal quenching.  As a thickening agent in tooth whitening gels. 
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5.5. Sodium lauryl sulfate 
Description:  
Sodium Lauryl Sulfate (SLS) is an anionic surfactant naturally derived from 
coconut and/or palm kernel oil. It usually consisting of a mixture of sodium alkyl sulfates, 
mainly the lauryl. SLS lowers surface tension of aqueous solutions and is used as fat 
emulsifier, wetting agent, and detergent in cosmetics, pharmaceuticals and toothpastes. It 
is also used in creams and pastes to properly disperse the ingredients and as research tool 
in protein biochemistry. SLS also has some microbicidal activity. 
Structure: 
                                                                                                                                                                 
Synonyms: 
Dodecyl alcohol, hydrogen sulfate, sodium salt 
Dodecyl sodium sulfate 
Dodecyl sulfate sodium 
Dodecyl sulfate sodium salt  
Lauryl sodium sulfate 
Lauryl sulfate sodium 
Lauryl sulfate sodium salt  
Lauryl sulfate, sodium salt  
Lauryl sodny [Czech] 
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Categories  : Surface-Active Agents 
Chemical Formula : C12H25NaO4S 
Mechanism of action: 
 Like other surfactants, SLS is amphiphilic. It thus migrates to the surface of 
liquids, where its alignment and aggregation with other SLS molecules lowers the surface 
tension. This allows for easier spreading and mixing of the liquid. SLS has potent protein 
denaturing activity and inhibits the infectivity of viruses by solubilizing the viral envelope 
and/or by denaturing envelope. 
Pharmacodynamic: SLS is an anionic surfactant. Its amphiphilic properties make it an 
ideal detergent. 
5.6. ȕ –CYCLODEXTRIN 
 Synonym                       :      Beta – cyclodextrin, ȕCD, BCD, ȕ-sachar 
                                                      Dextrin cyclodextrin B, cycloamyloses, 
                                  Cyclomaltoses and Schardinger dextrins 
 
Chemical formula        :       (C6H10O5)7 
 
Molecular weight         :         1135.00 
Solubility                       :         Sparingly soluble in water, freely soluble in hot         
                                         Water Slightly soluble in alcohol 
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Structure : 
                              
The chemical structure (A) and the toroidal shape (B) of the cyclodextrin molecule 
 
 
Table.7:  Some characteristics of (α, ȕ, Ȗ, δ). 
 
Type of CD Cavity diameter A Molecular weight Solubility(g/100ml) 
α – CD 4.7 – 5.3 972 14.5 
ȕ  - CD 6.0 – 6.52 1135 1.85 
Ȗ  - CD 7.5 – 8.3 1297 23.2 
δ  - CD 10.3 -11.2 1459 8.19 
 
Applications of cyclodextrin 
 
 Since each guest molecule is individually surrounded by a cyclodextrin 
(derivative) the molecule is micro-encapsulated from a microscopically point of view. 
This can lead to advantageous changes in the chemical and physical properties of the 
guest molecules. 
i. Stabilization of light or oxygen-sensitive substances. 
ii. Modification of the chemical reactivity of guest molecules. 
iii. Fixation of very volatile substances. 
iv. Improvement of solubility of substances. 
v. Modification of liquid substances to powders. 
vi. Protection against degradation of substances by 
microorganisms. 
vii. Masking of ill smell and taste. 
viii. Masking pigments or the color of substances. 
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6. MATERIALS 
6.1. INGREDIENTS USED: 
                           Table 8: Ingredients used for the experiment 
S.No Name of the ingredient Manufacturer/Suppliers 
1. Pitavastatin 
Spectrum lab,hyd 
 
2. Urea 
RankemPVT. Ltd,India 
 
 
3. PVP-k30 
RankemPVT. Ltd,India 
 
 
4. ȕ-cyclo dextrin 
Rankem PVT. Ltd,India 
 
 
5. Tween-80 
RankemPVT. Ltd,India 
 
6. SLS 
RankemPVT. Ltd,India 
 
 
7. Methanol 
Rankem PVT. Ltd,India 
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6.2. INSTRUMENTS USED: 
                                    Table 9: Instruments used for the experiment 
S.No 
NAME OF THE 
INSTRUMENT 
MANUFACTURING COMPANY 
1. Digital balance 
Shimadzu ELB 300 
 
2. 
Ultrasonic bath 
sonicator 
Bandelinsono plus model 
HD,2070 
3. 
Magnetic stirrer with 
hot plate, 
Eltek MS 2012 
4. 
Uv-spectophotometer 
 
Perkin elmer lambda25 
5. 
Dissolution apparatus 
US 
Labindia DS-800 
6. 
FT-IR 
spectrophotometer 
Perkin elmer spectrum RX1 
7. 
Scanning electron 
microscope 
Jobel model JSM 
6400,Tokyo 
8. Zeta potential analyser 
Zetasizer 3000 HS,Malvern 
instrument, UK 
9. 
Differential scanning 
calorimetry 
DSC DA 609 Shimadzu, 
japan 
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6.3METHODS 
1 .PREFORMULATION STUDIES 
[51, 52] 
Before formulation of drug substances into a dosage form, it is essential that the 
drug and polymer should be chemically and physically characterized. Preformulation 
studies give the information needed to define the nature of the drug substance and provide 
a framework for the drug combination with pharmaceutical excipients in the fabrication 
of a dosage form. 
Fourier Transform Infra Red Spectroscopy (FTIR) 
Compatibility study of Pitavastatin with the carrier’s urea, PVP, ȕ-cyclodextrin, 
and mixture of urea, PVP and ȕ-cyclodextrin used to formulate nanosuspension was 
determined by FTIR Spectroscopy using Perkin Elmer RX1. Spectral analysis of 
pitavastatin, urea, PVP and ȕ-cyclodextrin and combination was carried out to investigate 
the changes in chemical composition of the drug after combining it with excipients. The 
compatibility study on FTIR was carried by JASCO FT/IR 4100, MD, and USA in the 
frequency range 4000-400cm-1 
Differential Scanning Calorimetry (DSC): 
Differential scanning calorimetric curve of pure Pitavastatin, PVP, urea ȕ-
cyclodextrin and mixture of drug and carriers measurement were carried out by using a 
thermal analysis instrument equipped with a liquid nitrogen sub ambient accessory. First, 
a suspension sample of about 10 mg was placed in an aluminum pan, hermetically sealed 
before being placed in the calorimeter thermocouples. All samples were weighed (8-10 
mg) and heated at a scanning rate of 10°C/min under dry nitrogen flow (100 ml/min) 
between 50 and 300° C, Pure water and indium were used to calibrate the DSC 
temperature scale and enthalpy response. 
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6.4. ESTIMATION OF PURE PITAVASTATIN 
 
 Pitavastatin can be estimated spectrophotometrically at 241nm in the range of 3-
18 mcg/ml as per Beer Lambert’s law. 
Preparation of 0.1 N HCl:
 
Dissolve 8.5 ml of concentrated HCl in 1000 ml of distilled water. 
Preparation of standard drug solution: 
Stock solution: 
10 mg of Pitavastatin was dissolved in 10 ml of 0.1 N HCl, to get a solution of 
1000 µg/ml concentration. 
Standard solution: 
1 ml of stock solution was made to 10 ml with 0.1 N HCl thus giving a 
concentration of 100 µg/ml. Aliquot of standard drug solution ranging from 0.3ml, 0.6 
ml, 0.9 ml, 1.2 ml,1.5ml and 1.8 ml were transferred into 10 ml volumetric flask and were 
diluted up to the mark with 0.1 N HCl. Thus the final concentration ranges from 3-18 
µg/ml. Absorbance of each solution was measured at 241 nm against 0.1 N HCl as a 
blank. A plot of concentrations of drug versus absorbance was plotted. 
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PREPARATION  OF   PITAVASTAIN   NANOSUSPENSION   BY 
NANOPRECIPITATION : 
The nanosuspension was obtained by the precipitation process. The drug pitavastatin 
was initially dissolved in 5 ml of methanol it is organic phase. The organic phase was 
slowly added drop wise with syringe in 10ml of 0.1N HCL aqueous phase containing 
carrier urea, PVP, ȕ-cyclodextrin and surfactants SLS and Tween 80 kept at room 
temperature with speed of 900-1000rpm. Speeds using Magnetic stirrers until all the drug 
solution completely added in to surfactant solution and methanol completely evaporate 
from the solution. 
 
                                                   
Fig: 9 Photograph of the nanosuspension showing bluish opalescence. 
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                                      Table 10:  Formulation of pitavastatin nanosuspensions 
FORMULATION PITAVASTATIN UREA PVP30 ȕ-CD SLS TWEEN 80 WATER METHANOL 
F0 10mg --- --- --- --- --- 10ml 5ml 
F1 10mg 20mg --- --- --- --- 10ml 5ml 
F2 10mg --- 20mg --- --- --- 10ml 5ml 
F3 10mg --- --- 20mg --- --- 10ml 5ml 
F4 10mg 20mg --- --- 5mg --- 10ml 5ml 
F5 10mg --- 20mg --- 5mg --- 10ml 5ml 
F6 10mg --- --- 20mg 5mg --- 10ml 5ml 
F7 10mg 20mg --- --- --- 0.1ml 10ml 5ml 
F8 10mg --- 20mg --- --- 0.1ml 10ml 5ml 
F9 10mg --- --- 20mg --- 0.1ml 10ml 5ml 
F10 10mg 30mg --- --- 10mg --- 10ml 5ml 
F11 10mg --- 30mg --- 10mg --- 10ml 5ml 
F12 10mg --- --- 30mg 10mg --- 10ml 5ml 
F13 10mg 30mg --- --- --- 0.2ml 10ml 5ml 
F14 10mg --- 30mg --- --- 0.2ml 10ml 5ml 
F15 10mg --- --- 30mg --- 0.2ml 10ml 5ml 
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EVALUATION OF PITAVASTAIN NANOSUSPENSION 
Fourier Transform Infra Red Spectroscopy (FTIR) 
Compatibility study of Pitavastatin with the carrier’s urea, PVP, ȕ-cyclodextrin, 
and mixture of urea, PVP and ȕ-cyclodextrin used to formulate nanosuspensions was 
determined by FTIR Spectroscopy using Perkin Elmer RX1. Spectral analysis of 
Pitavastatin, urea, PVP and ȕ-cyclodextrin and combination was carried out to investigate 
the changes in chemical composition of the drug after combining it with excipients. The 
compatibility study on FTIR was carried by JASCO FT/IR 4100, MD, and USA in the 
frequency range 4000-400 cm-1. 
Scanning Electron Microscopy (SEM):
 
Surface morphology of the specimen will be determined by using a scanning 
electron microscope (SEM), Model JSM 84 0A, JEOI, Japan. The samples are dried 
thoroughly in vaccum desicator before mounting on brass specimen studies, using double 
sided adhesive tape. Gold-palladium alloy of 120°A Knees was coated on the sample 
sputter coating unit (Model E5 100 Polaron U.K) in Argon at ambient of 8-10 with 
plasma voltage about 20mA. The sputtering was done for nearly 5 minutes to obtain 
uniform coating on the sample to enable good quality SEM images. The SEM was 
operated at low accelerating voltage of about 15KV with load current about 80mA.The 
condenser lens position was maintained between 4.4-5.1. The objective lens aperture has 
a diameter of 240 microns and working distance WD=39mm. 
Zeta potential measurement: 
 
Zeta potential of the suspension is measured by Malvern Zetasizer. The zeta sizer 
mainly consists of laser which is used to provide a light source to illuminate the particles 
within the sample. For zeta potential measurements this light splits to provide an incident 
and reference beam. The incident laser beam passes through the center of the sample cell, 
and the scattered light at an angle of about 130 is detected. Zetasizer software produces a 
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frequency spectrum from which the electrophoretic mobility hence the zeta potential is 
calculated. 
Thermal Analysis by Differential Scanning Calorimetry (DSC): 
DSC scans of the prepared lyophilized powdered drug sample and pure drug 
samples were recorded using DSC- Shimadzu 60 with TDA trend line software. All 
samples were weighed (8-10 mg) and heated at a scanning rate of 10°C/min under dry 
nitrogen flow (100 ml/min) between 50 and 300° C. Aluminum pans and lids were used 
for all samples. Pure water and indium were used to calibrate the DSC temperature scale 
and enthalpy response. 
Drug entrapment efficiency (DEE) 
The freshly prepared nanosuspension was centrifuged at 20,000 rpm for 20 min at 5 
_C temperature using cool ultracentrifuge. The amount of unincorporated drug was 
measured by taking the absorbance of the appropriately diluted 25 ml of supernatant 
solution at 241 nm using UV spectrophotometer against blank/control Nanosuspensions. 
DEE was calculated by subtracting the amount of free drug in the supernatant from the 
initial amount of drug taken. The experiment was performed in triplicate for each batch 
and the average was calculated [53]. 
The entrapment efficiency (EE %) could be achieved by the following equation: 
 
Particle Size Analysis:  
 
The particle size analysis was carried out using Microtac blue wave particle size 
analyzer. Before measurement the samples has to be diluted with de-ionized water to 
obtain a suitable Concentration for measurement. The results obtained for particle size 
distributions were used to confirm the formation of nano-sized particles. 
Saturation Solubility Studies: 
Saturation solubility measurements were assayed through ultraviolet absorbance 
determination at 241 nm using shimadzu UV-Visible spectrophotometer. The saturation 
solubility studies were carried out for both the unprocessed pure drug and different 
batches of lyophilized nanosuspensions. 10 mg of unprocessed pure drug and 
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nanosuspensions equivalent to 10 mg of Pitavastatin were weighed and separately 
introduced into 25 ml stoppered conical flask containing 10 ml distilled water. The flasks 
were sealed and placed in rotary shaker for 24 hrs at 37°C and equilibrated for 2 days. 
The samples were collected after the specified time interval, and it is filtered and 
analyzed. The diluted samples were analyzed using UV spectrophotometer at 241nm. 
 
Dissolution study: 
In vitro drug release studies were performed in USP apparatus-Type II using 
paddle method at rotation speed of 50 rpm. Dissolution was carried out in 0.1N HCL as a 
dissolution medium. The volume and temperature of the dissolution medium were 900 ml 
and 37.0 + 0.5oC. 5 ml of sample was withdrawn periodically (after 5minutes) and 
replaced with an equal volume of fresh 0.1N HCL up to 60min. Samples were suitably 
diluted and filtered through a filter paper (0.ββ ȝm, Whatman Inc., USA). The filtrate was 
then subject to the UV analysis against the blank (distilled water). Percent cumulative 
release of SS was calculated based on the standard UV calibration curve at 241nm 
(Systronic 2203, Japan). 
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7. RESULT 
      
GRAPH NO: 1 Ȝmax OF PITAVASTATIN 
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TABLE 11: DATA FOR STANDARD CALIBRATION CURVE OF 
PITAVASTAIN DRUG IN0.1N HCL BUFFER: 
S.No Concentration (µg/ml) Absorbance (241nm) 
1. 0 0 
2. 3 0.151 
3. 6 0.287 
4. 9 0.425 
5. 12 0.562 
6. 15 0.699 
7. 18 0.837 
 Slope 0.04603 
 Regression 0.9999 
 
                  STANDARD CURVE FOR PITAVASTATIN IN 0.1N HCL AT 241nm 
  
Graph No: 2 Con. [µg/ml] 
 
69 
 
Preformulation study:   
Identification: 
Determination of melting point: 
Melting point of pitavastatin was found to be in the range of 190-1920c as reported 
in the literature, thus indicating purity of sample. If any impurity will present, will cause 
variation in the melting point of a given drug substance. The melting point of the obtained 
drug was found to be 1910C. Hence the obtained drug was found to be pure without any 
impurities. 
Solubility: 
Pitavastatin is very slightly soluble in water. Very soluble in pyridine, chloroform, 
dilute hydrochloric acid, tetrahydrofuran , soluble in ethylene glycol, sparingly soluble in 
octanol, slightly soluble in methanol. 
Drug entrapment efficiency: 
The formulations showed drug entrapment in the range of 84–92 %. Formulation 
(Fp15) containing drug concentration 80 mg/ml stabilised with ȕ-cyclodextrin showed 
highest entrapment up to λβ % w/v. Formulations containing ȕ-cyclodextrin showed 
better entrapment in comparison to PVP, urea. 
Particle Size Analysis: 
The particle size distribution studies showed that all the formulation particle size 
was in the range of 443-446 nm and where as unprocessed drug shows 50.5± 0.07ȝm 
sizes. All the formulations having a particle size in the nanometre range and showing 
ideal surface morphology. 
Saturation Solubility Studies: 
The saturation solubility studies indicating that nanosuspensions showing maximum 
solubility Compared to unprocessed drug which are due to the amorphous nature of drug. 
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Table 12: Results of solubility and drug entrapment efficiency. 
Studies of Formulation and Pure Drug 
Sample Solubility (ȝg/ml) Drug entrapment 
F0 132 ---- 
F1 209 54 
F2 253 57 
F3 287 60 
F4 312 63 
F5 334 67 
F6 378 70 
F7 402 73 
F8 436 75 
F9 628 78 
F10 499 81 
F11 521 84 
F12 548 86 
F13 592 87 
F14 475 90 
F15 651 92 
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Differential scanning colorimetry: 
The physical state of raw pitavastatin and lyophilized drug nanoparticles was 
examined by DSC. The DSC of pitavastatin shows an endothermic curve at its melting 
point 184.λ°C (ΔH = -15.80 J/g) and the precipitated drug shows an endothermic peak at 
γ00. 7°C (ΔH = -16.43J/g). The complete absence of pitavastatin peak indicates that 
pitavastatin is present as amorphous after being precipitated as nanoparticles it reduced 
crystallinity. 
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Compatibility studies: 
FT-IR spectroscopy was carried out to study the compatibility of pure pitavastatin 
drug with ȕ-cyclodextrin carrier and Tween 80 used in the formulation of 
nanosuspensions. The physical mixture has characteristic IR peaks at 1026.14 C-F(alkyl 
halide), 1153.07 C-F(alkyl halide) ,696.33 C-Cl(alkyl halide), 753.22 C-Cl(alkyl 
halide).The pitavastatin has characteristic IR peaks at 1520.07 C=C(Aromatic), 3738.54 
O-H(Alcohol), 1436.76-C-H(Alkane), 1321.31 C-N(Amine).The ȕ-cyclodextrin has 
characteristic IR peaks at 3392.14 N-H(Amine), 2927.62 C-H(Alkane), 1029.36 C-
F(alkyl halide), 577.98 C-Br(Alkyl Halide).The tween80 has characteristic peaks IR at 
3382.76 O-H(Alcohol), 2922.28 C-H(Alkane). 2339.80 C-N (Nitrile), 1540.30 C=C 
(Aromatic). 
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             Table: 13 pitavastatin nanosuspension of ȕ-cyclodextrin & Tween 80 
 
S.No 
 
IR Spectrum 
 
Peaks(cm
-1) 
 
Grou
ps 
Stretching 
/Deformation 
 
 
 
1
 
 
Pitavastatin 
nanosuspensions 
of ȕ-cyclodextrin 
and tween80 
 
 
1026.14 
 
C-F(alkyl halide) 
 
Stretching 
1153.07 C-F(alkyl halide) Stretching 
 
696.33 
C-Cl(alkyl 
halide) 
 
Stretching 
753.22 C-Cl(alkyl halide) Stretching 
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                                                  Table 14: Pure pitavastatin  
 
 
S.No 
 
 
IR Spectrum 
 
 
Peaks(cm
-1) 
 
 
Groups 
Stretching 
/Deformation 
 
 
 
 
1 
 
 
 
 
Pitavastatin 
 
1520.07 
 
C=C(Aromatic) 
 
Stretching 
3738.54 O-H(Alcohol) Stretching 
 
1436.76 
-C-H(Alkane)  
Stretching 
1321.31 C-N(Amine) Stretching 
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                                                       Table 15μ ȕ-cyclodextrin 
 
 
S.No 
 
 
IR Spectrum 
 
 
Peaks(cm
-1) 
 
 
Groups 
Stretching 
/Deformation 
 
 
 
 
1 
 
 
 
 
ȕ-cyclodextrin 
 
3392.14 
 
      N-H(Amine) 
 
Stretching 
2927.62 C-H(Alkane) Stretching 
 
1029.36 
      C-F(alkyl halide)  
Stretching 
577.98 C-Br(Alkyl Halide) Stretching 
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                                                         Table 16: Tween 80 
 
 
S.No 
 
 
IR Spectrum 
 
 
Peaks(cm
-1) 
 
 
      Groups 
Stretching 
/Deformation 
 
 
 
 
1 
 
 
 
 
Tween80 
 
3382.76 
 
     O-H(Alcohol) 
 
Stretching 
2922.28      C-H(Alkane) Stretching 
 
2339.80 
     C-N(Nitrile)  
Stretching 
1540.30      C=C(Aromatic) Stretching 
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Shape and surface morphology: 
 Nanoparticle surface morphology and shape were visualized using SEM (JSM-
T330A, JEOL). The drug loaded nanoparticles were found to be spherical with smooth 
surface. 
 
                 SCANNING ELECTRON MICROSCOPY OF PURE PITAVASTATIN 
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                 SCANNING ELECTRON MICROSCOPY FOR 
FORMULATION15
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ZETA POTENTIAL:  
Zeta potential is a term related to the stability of samples for molecules and particles 
that are small enough, high zeta potential will confer stability i.e.it resist aggregation 
.Here zeta potential of the prepared nanosuspension was found to be -34.4,which would 
not allow aggregation
82 
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IN-VITRO DRUG RELEASE CHARACTRISTICS OF PITAVASTAIN 
NANOSUSPENSION  
  In-vitro release behavior of Pitavastatin is summarized in tables; in-vitro drug release 
from the nanosuspensions in 0.1N HCL buffer was performed. The in-vitro drug release 
profile of nanosuspensions formulations obtained from experiment was shown in table. 
 The release rate profiles were drawn as the percentage pitavastatin dissolved from the 
nanosuspensions and pure drug versus time. Dissolution studies of pure pitavastatin and 
all other prepared nanosuspensions (F0- F15) were carried out in 0.1N HCL. T90% (time 
to dissolve 90% drug) values calculated from release profile are reported. From this data, 
it was evident that onset of dissolution of pure pitavastatin was very low. Dissolution of 
pitavastatin nanosuspensions was affected by different surfactant concentrations and 
organic to aqueous solvent ratio. It can be observed that, 80% of the pitavastatin 
nanosuspensions were dissolved in 5min; while in the same period, 2.16% of the raw 
pitavastatin was dissolved. According to Noyes–Whitney equation, the dissolution rate is 
directly proportional to its surface area exposed to the dissolution medium. The increase 
dissolution for drug nanoparticles could thus be mainly ascribed to their greater surface 
area in comparison with raw drug. 
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Table 17: Dissolution profile of formulation (F0) in 0.1N HCL 
Time 
(min) 
Cumulative Percent Drug Release 
Trial 1 Trial2 Trial3 Mean ± SD 
0 0 0 0 0 
5 2.16 2.01 1.98 2.05±0.09643 
10 6.49 6.57 6.23 6.43±0.17776 
15 7.47 7.82 7.09 7.46±0.35529 
20 11.01 10.89 11.33 11.07±0.22774 
25 18.10 18.24 17.98 18.10±0.13012 
30 21.05 21.33 21.68 21.35±0.31564 
45 24.00 24.47 24.23 24.23±0.23501 
60 29.11 29.37 29.00 29.16±0.19 
                                                                                                                                                                         
                      
       Graph No.3: In-Vitro Drug Release of F0 
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Table 18: Dissolution profile of formulation (F1) in ph 0.1N HCL 
Time 
(min) 
Cumulative Percent Drug Release 
Trial 1 Trial 2 Trial 3 Mean ± SD 
0 0 0 0 0 
5 12.59 12.37 12.73 12.56±0.18147 
10 25.96 25.65 25.57 25.72±0.20599 
15 29.90 29.73 29.48 29.70±0.21126 
20 32.46 32.89 32.17 32.50±0.36226 
25 34.23 34.69 34.09 34.33±0.31390 
30 36.98 36.69 36.86 36.84±0.14571 
45 39.34 39.19 39.78 39.43±0.30664 
60 40.33 40.15 40.25 40.24±0.09018 
 
                     
Graph No.4: In-Vitro Drug Release  
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Table 19:  Dissolution profile of formulation (F2) in ph 0.1N HCL 
Time 
(min) 
        Cumulative Percent Drug Release 
Trial 1 Trial 2 Trial 3 Mean ± SD 
0 0 0 0 0 
5 5.50 5.32 5.69 5.50±0.18502 
10 7.47 7.60 7.76 7.61±0.14525 
15 19.28 19.04 18.94 19.08±0.17473 
20 23.21 23.15 23.26 23.20±0.05507 
25 24.59 24.92 24.23 24.58±0.34510 
30 29.90 29.43 29.35 29.56±0.29715 
45 31.87 31.74 31.92 31.84±0.09291 
60 35.80 35.52 35.65 35.65±0.14011 
 
              
               Graph No.5: In-Vitro Drug Release of F2          
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Table 20: Dissolution profile of formulation (F3) in 0.1N HCL 
Time 
(min) 
          Cumulative Percent Drug Release 
Trial 1 Trial 2 Trial 3 Mean ± SD 
0 0 0 0 0 
5 14.16 14.22 13.95 14.11±0.14177 
10 22.03 22.19 21.87 22.03±0.16 
15 26.55 26.37 26.09 26.33±0.23180 
20 29.51 29.08 29.27 29.28±0.21548 
25 31.28 31.15 30.92 31.11±0.18230 
30 36.39 36.67 36.47 36.51±0.14422 
45 40.92 40.74 40.49 40.71±0.121594 
60 43.67 43.60 43.48 43.58±0.09609 
 
                
Graph No.6: In-Vitro Drug Release of F3 
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Table 21: Dissolution profile of formulation (F4) in 0.1N HCL 
Time 
(min) 
          Cumulative Percent Drug Release 
Trial 1 Trial 2 Trial 3 Mean ± SD 
0 0 0 0 0 
5 11.23 11.09 10.97 11.09±0.13012 
10 13.37 12.92 13.19 13.16±0.22649 
15 21.24 21.11 21.00 21.11±0.12013 
20 27.15 26.87 26.99 27.00±0.14047 
25 49.57 49.32 49.18 49.35±0.19756 
30 56.66 56.42 56.74 56.60±0.16653 
45 68.46 68.27 67.96 68.23±0.25238 
60 76.33 76.13 75.94 76.13±0.195021 
 
                  
                                                 Graph No.7: In-Vitro Drug Release of F 
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Table 22: Dissolution profile of formulation (F5) in 0.1N HCL 
Time 
(min) 
          Cumulative Percent Drug Release 
Trial 1 Trial 2 Trial 3 Mean ± SD 
0 0 0 0 0 
5 22.62 22.11 22.43 22.38±0.25774 
10 36.2 35.90 36.17 36.09±0.16522 
15 41.31 41.13 40.89 41.11±0.21071 
20 47.21 46.94 47.39 47.18±0.22649 
25 56.46 56.91 56.72 56.69±0.22590 
30 58.62 58.29 58.50 58.47±0.16703 
45 60.59 59.97 60.27 60.27±0.31005 
60 72.40 72.13 71.89 72.14±0.25514 
 
                      
                  Graph No.8: In-Vitro Drug Release  
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 Table 23: Dissolution profile of formulation (F6) in 0.1N HCL 
Time 
(min) 
        Cumulative Percent Drug Release 
Trial 1 Trial 2 Trial 3 Mean ± SD 
0 0 0 0 0 
5 19.28 18.93 19.01 19.07±0.18339 
10 34.62 33.92 33.72 34.08±0.47258 
15 46.03 45.73 46.36 46.04±0.31511 
20 52.72 52.43 52.60 52.58±0.14571 
25 65.31 65.52 65.22 65.35±0.15394 
30 68.46 67.92 68.29 68.22±0.27610 
45 71.21 70.89 71.43 71.17±0.2753 
60 81.45 80.67 80.97 81.03±0.39344 
 
                   
      Graph No.9: In-Vitro Drug Release of F6 
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Table 24: Dissolution profile of formulation (F7) in 0.1N HCL 
Time 
(min) 
            Cumulative Percent Drug Release 
Trial 1 Trial 2 Trial 3 Mean ± SD 
0 0 0 0 0 
5 34.62 34.26 34.41 34.43±0.18083 
10 45.25 44.96 45.09 45.10±0.14525 
15 54.10 53.87 54.37 54.11±0.25026 
20 73.18 73.69 72.92 73.26±0.39170 
25 82.23 82.36 81.96 82.18±0.20404 
30 98.36 98.57 98.19 98.37±0.19035 
 
                        
              Graph No.10: In-Vitro Drug Release of F7 
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Table 25: Dissolution profile of formulation (F8) in 0.1N HCL 
Time 
(min) 
         Cumulative Percent Drug Release 
Trial 1 Trial 2 Trial 3 Mean ± SD 
0 0 0 0 0 
5 22.62 22.25 21.90 22.25±0.36004 
10 36.39 35.87 36.46 36.24±0.32233 
15 41.70 41.53 41.87 41.70±0.17 
20 59.02 58.87 59.21 59.03±0.17039 
25 80.46 80.66 80.05 80.39±0.31096 
30 89.51 89.33 88.92 89.25±0.30237 
45 97.00 96.73 96.92 96.88±0.13864 
 
                      
            Graph No.11: In-Vitro Drug Release of F8 
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Table 26: Dissolution profile of formulation (F9) in 0.1N HCL 
Time 
(min) 
           Cumulative Percent Drug Release 
Trial 1 Trial 2 Trial 3 Mean ± SD 
0 0 0 0 0 
5 34.42 34.19 33.78 34.13±0.32419 
10 39.15 38.81 38.69 38.88±0.23860 
15 56.85 56.43 56.19 56.49±0.33406 
20 71.21 71.09 70.67 70.99±0.28354 
25 91.48 91.84 91.09 91.47±0.37509 
30 100.33 100.10 99.89 100.10±0.22007 
 
                       
Graph No.12: In-Vitro Drug Release of F 
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 Table 27: Dissolution profile of formulation (F10) in 0.1N HCL 
Time 
(min) 
            Cumulative Percent Drug Release 
Trial 1 Trial 2 Trial 3 Mean ± SD 
0 0 0 0 0 
5 52.13 51.87 52.57 52.19±0.35383 
10 65.90 65.61 65.23 65.58±0.33600 
15 76.13 75.94 76.29 76.12±0.13868 
20 85.58 85.15 85.37 85.36±0.21501 
25 96.20 96.54 96.38 96.37±0.17009 
 
                    
Graph No.13: In-Vitro Drug Release of F10 
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Table 28: Dissolution profile of formulation (F11) in 0.1N HCL 
Time 
(min) 
         Cumulative Percent Drug Release 
Trial 1 Trial 2 Trial 3 Mean ± SD 
0 0 0 0 0 
5 46.03 45.90 46.23 46.05±0.56092 
10 56.66 56.23 56.87 56.58±0.32624 
15 65.90 65.61 65.40 65.63±0.25106 
20 78.10 77.87 78.43 78.13±0.28148 
25 93.05 92.76 93.23 93.01±0.237135 
30 100.53 100.37 100.19 100.36±0.170098 
 
                     
Graph No.14: In-Vitro Drug Release of F11 
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 Table 29: Dissolution profile of formulation (F12) in 0.1N HCL 
Time 
(min) 
           Cumulative Percent Drug Release 
Trial 1 Trial 2 Trial 3 Mean ± SD 
0 0 0 0 0 
5 53.31 53.19 52.96 53.15±0.17857 
10 73.18 73.69 73.41 73.42±0.25540 
15 92.81 93.26 92.66 92.81±0.38940 
20 103.28 103.09 102.87 103.11±0.21548 
 
                     
Graph No.15: In-Vitro Drug Release of F12 
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Table 30: Dissolution profile of formulation (F13) in 0.1N HCL 
Time 
(min) 
           Cumulative Percent Drug Release 
Trial 1 Trial 2 Trial 3 Mean ± SD 
0 0 0 0 0 
5 89.51 89.63 89.15 89.43±0.24979 
10 96.40 96.19 96.58 96.39±0.19519 
15 100.14 99.89 100.24 100.09±0.18027 
 
                      
Graph No.15: In-Vitro Drug Release of F13 
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Table 31:  Dissolution profile of formulation (F14) in 0.1N HCL 
Time 
(min) 
          Cumulative Percent Drug Release 
Trial 1 Trial 2 Trial 3 Mean ± SD 
0 0 0 0 0 
5 78.30 77.90 78.02 77.74±0.20526 
10 92.07 91.93 92.39 92.12±0.22479 
15 98.17 98.28 98.39 98.28±0.11 
 
                     
Graph No.17: In-Vitro Drug Release of F14 
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Table 32: Dissolution profile of formulation (F15) in 0.1N HCL 
Time 
(min) 
Cumulative Percent Drug Release 
Trial 1 Trial 2 Trial 3 Mean ± SD 
0 0 0 0 0 
5 82.88 82.54 82.27 82.56±0.30566 
10 98.87 99.01 98.93 98.93±296.81 
 
                        
Graph No.18: In-Vitro Drug Release of F15 
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      Table no: 33 Comparative cumulative % drug release of formulations F0-F15 
 
 
Cumulative Percent Drug Release (%) 
TIME F0 F1 F2 F3 F4 
0 0 0 0 0 0 
5 2.05±0.09643 12.56±0.18147 5.50±0.18502 14.11±0.14177 11.09±0.13012 
10 6.43±0.17776 25.72±0.20599 7.61±0.14525 22.03±0.16 13.16±0.22649 
15 7.46±0.35529 29.70±0.21126 19.08±0.17473 26.33±0.23180 21.11±0.12013 
20 11.07±0.22774 32.50±0.36226 23.20±0.05507 29.28±0.21548 27.00±0.14047 
30 18.10±0.13012 34.33±0.31390 24.58±0.34510 31.11±0.18230 49.35±0.19756 
45 21.35±0.31564 36.84±0.14571 29.56±0.29715 36.51±0.14422 56.60±0.16653 
60 24.23±0.23501 39.43±0.30664 31.84±0.09291 40.71±0.121594 68.23±0.25238 
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Cumulative Percent Drug Release (%) 
TIME F5 F6 F7 F8 F9 
0 0 0 0 0 0 
5 22.38±0.25774 19.07±0.18339 34.43±0.18083 22.25±0.36004 34.13±0.32419 
10 36.09±0.16522 34.08±0.47258 45.10±0.14525 36.24±0.32233 38.88±0.23860 
15 41.11±0.21071 46.04±0.31511 54.11±0.25026 41.70±0.17 56.49±0.33406 
20 47.18±0.22649 52.58±0.14571 73.26±0.39170 59.03±0.17039 70.99±0.28354 
25 56.69±0.22590 65.35±0.15394 82.18±0.20404 80.39±0.31096 91.47±0.37509 
30 58.47±0.16703 68.22±0.27610 98.37±0.19035 89.25±0.30237 100.10±0.22007 
45 60.27±0.31005 71.17±0.2753  96.88±0.13864  
60 72.14±0.25514 81.03±0.39344    
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                                                                       Cumulative Percent Drug Release (%) 
TIME F10 F11 F12 F13 F14 
       F15 
0 0 0 0 0 0 
0 
5 52.19±0.35383 46.05±0.56092 53.15±0.17857 89.43±0.24979 77.74±0.20526 82.56±0.30566 
10 65.58±0.33600 56.58±0.32624 73.42±0.25540 96.39±0.19519 92.12±0.22479 98.93±296.81 
15 76.12±0.13868 65.63±0.25106 92.81±0.38940 100.09±0.18027 98.28±0.11 
 
20 85.36±0.21501 78.13±0.28148 103.11±0.21548   
 
25 96.37±0.17009 93.01±0.237135 53.15±0.17857   
 
30  100.36±0.170098    
 
45      
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             COMPARATIVE STUDY OF NANOSUSPENSION FORMULATIONS 
 
Graph No.19: In-Vitro Drug Release of F1-F15 
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  8. DISCUSSION 
Pitavastatin –lipid lowering drug used in the treatment of hypercholesterolemia 
currently available as tablet dosage form belongs to BCS class-II drug having low 
solubility and high permeability. Therefore it is poorly bioavailable any attempt that can 
enhance the solubility of pitavastatin can show improved bioavailability of drug. 
Considering this the present study aimed to prepare nanosuspension of pitavastatin and 
evaluate the formulation for its physico-chemical properties and in-vitro release studies. 
 
Among the various pharmaceutical approaches, nanoparticle approach assumes 
significance today as this approach influences physico-chemical properties as well as 
biological property of the drug. Based on this factor pitavastatin in the present study was 
attempted as nanosuspension. Different approaches have been reported for the preparation 
of nanosuspension. In the present study nanoprecipitation method was chosen because the 
method of preparation is simple to follow at laboratory scale, can ensure small particle 
formulation besides other advantages. Many factors influence the particle size of 
nanosuspension, of which particularly the influence of carriers of nanosuspension is of 
importance. In this study the pitavastatin nanosuspension were prepared using different 
carriers such as urea,PVPγ0,ȕ-cyclodextrin,SLS and Tween 80,the proportion of these 
carriers in the formulations were selected upon the earlier study on simvastatin.(  Vikram 
M. Pandya et al 2011).Formulations F0-F15 were developed using different carriers. A 
Preformulation study by FTIR spectral analysis revels that there was no chemical 
interaction between the drug and carriers. 
 
 The particle size of pitavastatin was significantly reduced from 50µm to 446nm 
for the formulation F15.The least particle size was observed with formulation F15 
containing ȕ-cyclodextrin and Tween 80.Our finding suggest that beyond the particle size 
change some other factors related to the carrier used may be predominantly influencing 
the solubility of pitavastatin. Overall analysis by pitavastatin nanosuspension suggests the 
particle size or the solubility of nanosuspension appears dependent on the carrier 
characteristics and the concentration of the carriers. 
 
The drug entrapment of the nanosuspension was found to high (92%) with F15 
containing ȕ-cyclodextrin and Tween 80 whereas the least drug entrapment was observed 
in F1 (54%) containing urea. All the carriers showed drug entrapment above 54%.An 
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increase interaction between the drug and the carrier results in increased in drug 
entrapment. 
 
The dissolution profiles of the various formulations are shown in table 33 and 
graph 19. Each formulation showed variable percentage drug dissolved in over time. Pure 
Pitavastatin showed 29.1% drug release in 60 mins indicating poor solubility 
characteristics and therefore slow dissolution of the drug. Among the nanosuspensions the 
formulation F15 showed highest dissolution of drug 98.93% in the shortest time. The 
least percentage drug release (35.65%) was observed in formulation F2 containing 
PVP30. 
 
The poor dissolution from PVP30 carrier may be due to increase in viscosity of 
the environmental media broughtout by PVP30 that acts as a barrier to diffusion and 
dissolution of drug in the environment. From the dissolution profile of nanosuspensions it 
is understood the carrier characteristics appear significantly influencing the dissolution of 
the drug. Comparison of the dissolution profile of various formulations reveals that F15 
appears the best formulation as it showed highest percentage drug release in shortest time 
.ȕ-cyclodextrin present in the F15 along with Tween 80 as stabilising agent may be 
influencing a great extent the solubility and therefore the dissolution of pitavastatin .The 
mechanism of the dissolution of the best formulation F15 was examined for their surface 
characteristics and DSC thermogram. The DSC thermogram of F15 showed the shifting 
of the endothermic peak of Pitavastatin from 184-300 °C indicating amorphous 
formulation of drug in the nanosuspension .Amorphous form of drug is more soluble as 
compared to its crystalline form and therefore the enhanced solubility and dissolution in 
F15 may be due to the existence of the drug in amorphous state in nanosuspension. 
 
A stable nanosuspension should have zeta potential greater than ±25mv, since 
higher value of zeta potential produce repulsive force between the particles in 
nanosuspension, thus prevent aggregation of particles dispersed and thus stabilise the 
nanosuspension. From this study it is evident that the zeta potential of the formulation 
F15 was found to be -34.4 mV and thus ensuring the stability of formulation F15 
nanosuspension.      
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9. CONCLUSION 
The results of the present study demonstrate that nanoprecipitation technique was 
employed to produce nanoparticles of pitavastatin, a poorly water-soluble drug, for the 
improvement of solubility and dissolution velocity. In this process, the particle size of 
pitavastatin can be obtained in the nano-size ranges, by adjusting the operation 
parameters. The best nanosuspension of pitavastatin can be obtained by 10mg, ȕ-
cyclodextrin 30mg, and 0.2% w/v Tween 80. Thus it can be concluded that the 
dissolution of pitavastatin is significantly increased when it is nanosized and thus the 
bioavailability can be increased compared with the pure pitavastatin. 
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